Kent County Memorial Hospital: drugs
Schedule G of this filing lists 387 drugs, with an amount and a number of claims for each, as filed. Every amount links to its page of the filing.
The schedule's total is printed as “Total Costs of Prescription Drugs Obtained Through 340B Program Claimed for Reimbursement”. The filings describe the amounts in more than one way. Methods says more.
- 387drugs listed
- $44,095,350.32 (Schedule G, printed total, page 20 of the filing PDF)Total as filed
- 332,510 (Schedule G, printed claims total, page 20 of the filing PDF)Claims total as filed
- 65rows show “fewer than 6” for claims. What this means
All 387 drug rows
| Line | Drug | Amount as filed | Claims as filed |
|---|---|---|---|
| 1 | Kesimpta 20 mg/0.4 mL pen00078100768Listed by the FDA as Kesimptaofatumumab20 mg/0.4 mLinjection, solutionNovartis Pharmaceuticals Corporation | 1,933,416.47 (Schedule G, line 1, page 10 of the filing PDF) | 276 |
| 2 | pembrolizumab 100 mg/4 mL INJ00006302602Listed by the FDA as Keytrudapembrolizumab25 mg/mLinjection, solutionMerck Sharp & Dohme LLC | 1,559,990.40 (Schedule G, line 2, page 10 of the filing PDF) | 171 |
| 3 | daratumumab-hyaluronidase 1,800 mg-30,000 units INJ 15 mL7894050301 | 1,240,777.54 (Schedule G, line 3, page 10 of the filing PDF) | 206 |
| 4 | Brukinsa 80 mg capsule72579001102Listed by the FDA as Brukinsazanubrutinib80 mgcapsuleBeOne Medicines USA, Inc. | 1,181,074.04 (Schedule G, line 4, page 10 of the filing PDF) | 128 |
| 5 | Dupixent 300 mg/2 mL pen00024591502Listed by the FDA as Dupixentdupilumab300 mg/2 mLinjection, solutionSanofi-Aventis U.S. LLC | 1,168,095.81 (Schedule G, line 5, page 10 of the filing PDF) | 171 |
| 6 | Tagrisso 80 mg tablet00310135030Listed by the FDA as Tagrissoosimertinib80 mgtablet, film coatedAstraZeneca Pharmaceuticals LP | 1,119,735.99 (Schedule G, line 6, page 10 of the filing PDF) | 91 |
| 7 | Ofev 150 mg capsule00597014560Listed by the FDA as Ofevnintedanib150 mgcapsuleBoehringer Ingelheim Pharmaceuticals, Inc. | 996,080.90 (Schedule G, line 7, page 10 of the filing PDF) | 112 |
| 8 | Calquence 100 mg tablet00310351260Listed by the FDA as Calquenceacalabrutinib100 mgtablet, film coatedAstraZeneca Pharmaceuticals LP | 958,829.00 (Schedule G, line 8, page 10 of the filing PDF) | 103 |
| 9 | MPB Opdivo 240 mg/24 mL SDV00003373413Listed by the FDA as Opdivonivolumab10 mg/mLinjectionE.R. Squibb & Sons, L.L.C. | 866,349.21 (Schedule G, line 9, page 10 of the filing PDF) | 154 |
| 10 | Nubeqa 300 mg tablet50419039501Listed by the FDA as Nubeqadarolutamide300 mgtablet, film coatedBayer HealthCare Pharmaceuticals Inc. | 693,979.05 (Schedule G, line 10, page 10 of the filing PDF) | 88 |
| 11 | Humira(CF) pen 40 mg/0.4 mL00074055402Listed by the FDA as HumiraadalimumabkitAbbVie Inc. | 631,773.90 (Schedule G, line 11, page 10 of the filing PDF) | 376 |
| 12 | Nucala 100 mg/mL auto-injector00173089201Listed by the FDA as Nucalamepolizumab100 mg/mLinjection, solutionGlaxoSmithKline LLC | 605,715.89 (Schedule G, line 12, page 10 of the filing PDF) | 87 |
| 13 | ivosidenib 250 mg Tab72694061760Listed by the FDA as Tibsovoivosidenib250 mgtablet, film coatedServier Pharmaceutical LLC | 592,600.36 (Schedule G, line 13, page 10 of the filing PDF) | 26 |
| 14 | venetoclax (Venclexta) 100 mg Tab00074057622Listed by the FDA as Venclextavenetoclax100 mgtablet, film coatedAbbVie Inc. | 559,576.98 (Schedule G, line 14, page 10 of the filing PDF) | 95 |
| 15 | Verzenio 100 mg tablet00002481554Listed by the FDA as Verzenioabemaciclib100 mgtabletEli Lilly and Company | 535,284.40 (Schedule G, line 15, page 10 of the filing PDF) | 9 |
| 16 | Skyrizi 150 mg/mL pen00074210001Listed by the FDA as Skyrizirisankizumab-rzaa150 mg/mLinjectionAbbVie Inc. | 528,240.25 (Schedule G, line 16, page 10 of the filing PDF) | 32 |
| 17 | tafamidis 61 mg cap00069873030Listed by the FDA as Vyndamaxtafamidis61 mgcapsule, liquid filledPfizer Laboratories Div Pfizer Inc | 525,724.66 (Schedule G, line 17, page 10 of the filing PDF) | 31 |
| 18 | palbociclib (Ibrance) 75 mg Tab00069028403Listed by the FDA as Ibrancepalbociclib75 mgtablet, film coatedPfizer Laboratories Div Pfizer Inc | 503,801.00 (Schedule G, line 18, page 10 of the filing PDF) | 56 |
| 19 | ravulizumab-cwvz 300 mg/3 mL INJ25682002501Listed by the FDA as Ultomirisravulizumab300 mg/3 mLsolution, concentrateAlexion Pharmaceuticals Inc. | 475,610.73 (Schedule G, line 19, page 10 of the filing PDF) | 10 |
| 20 | durvalumab (Imfinzi) 1,500 mg in sodium chloride 0.9% 250 mL IVPB00310461150Listed by the FDA as Imfinzidurvalumab500 mg/10 mLinjection, solutionAstraZeneca Pharmaceuticals LP | 466,661.08 (Schedule G, line 20, page 11 of the filing PDF) | 72 |
| 21 | Ofev 100 mg capsule00597014360Listed by the FDA as Ofevnintedanib100 mgcapsuleBoehringer Ingelheim Pharmaceuticals, Inc. | 462,673.60 (Schedule G, line 21, page 11 of the filing PDF) | 54 |
| 22 | teprotumumab (Tepezza) 500 mg injection75987013015Listed by the FDA as Tepezzateprotumumab500 mginjection, powder, lyophilized, for solutionHorizon Therapeutics USA, Inc. | 421,049.28 (Schedule G, line 22, page 11 of the filing PDF) | 8 |
| 23 | Mounjaro 5 mg/0.5 mL pen00002149580Listed by the FDA as Mounjarotirzepatide5 mg/0.5 mLinjection, solutionEli Lilly and Company | 408,777.81 (Schedule G, line 23, page 11 of the filing PDF) | 42 |
| 24 | talquetamab tgvs 40 mg/mL INJ57894047001Listed by the FDA as Talveytalquetamab-tgvs40 mg/mLinjectionJanssen Biotech, Inc. | 388,414.12 (Schedule G, line 24, page 11 of the filing PDF) | 49 |
| 25 | Verzenio 150 mg tablet00002533754Listed by the FDA as Verzenioabemaciclib150 mgtabletEli Lilly and Company | 368,827.48 (Schedule G, line 25, page 11 of the filing PDF) | 10 |
| 26 | MPB Tezspire 210 mg/1.91 mL pen55513012301Listed by the FDA as Tezspiretezepelumab-ekko210 mg/1.9 mLinjection, solutionAmgen Inc | 335,617.81 (Schedule G, line 26, page 11 of the filing PDF) | 121 |
| 27 | Privigen 40 g/400 mL SOLN44206043940Listed by the FDA as Privigenhuman immunoglobulin G40 g/400 mLliquidCSL Behring AG | 328,335.70 (Schedule G, line 27, page 11 of the filing PDF) | 148 |
| 28 | Cosentyx Snrdy 300 mg dose-2pen00078063941Listed by the FDA as Cosentyxsecukinumab150 mg/mLinjectionNovartis Pharmaceuticals Corporation | 307,517.32 (Schedule G, line 28, page 11 of the filing PDF) | 43 |
| 29 | Fasenra pen 30 mg/mL00310183030Listed by the FDA as Fasenrabenralizumab30 mg/mLinjection, solutionAstraZeneca Pharmaceuticals LP | 288,508.19 (Schedule G, line 29, page 11 of the filing PDF) | 76 |
| 30 | Kcentra 1,000 units KIT63833038702Listed by the FDA as Kcentraprothrombin, coagulation factor VII human, coagulation factor IX human, coagulation factor X human, protein C, protein S human, and waterkitCSL Behring GmbH | 285,916.19 (Schedule G, line 30, page 11 of the filing PDF) | 82 |
| 31 | Ibrance tab 125 mg00069068803Listed by the FDA as Ibrancepalbociclib125 mgtablet, film coatedPfizer Laboratories Div Pfizer Inc | 279,800.77 (Schedule G, line 31, page 11 of the filing PDF) | 30 |
| 32 | Erbitux VL 2 mg/mL 100 mL66733095823Listed by the FDA as Erbituxcetuximab2 mg/mLsolutionImClone LLC | 279,398.77 (Schedule G, line 32, page 11 of the filing PDF) | 280 |
| 33 | Xtandi 40 mg tablet00469062599Listed by the FDA as Xtandienzalutamide40 mgtabletAstellas Pharma US, Inc. | 270,850.49 (Schedule G, line 33, page 11 of the filing PDF) | 50 |
| 34 | Skyrizi 360 mg/2.4 mL on-body00074107001Listed by the FDA as Skyrizirisankizumab-rzaakitAbbVie Inc. | 266,341.39 (Schedule G, line 34, page 11 of the filing PDF) | 27 |
| 35 | MPB Erleada 60 mg tab 12059676060012Listed by the FDA as Erleadaapalutamide60 mgtablet, film coatedJanssen Products, LP | 259,454.97 (Schedule G, line 35, page 11 of the filing PDF) | 26 |
| 36 | Privigen 20 g/200 mL SOLN44206043820Listed by the FDA as Privigenhuman immunoglobulin G20 g/200 mLliquidCSL Behring AG | 250,477.15 (Schedule G, line 36, page 11 of the filing PDF) | 220 |
| 37 | MPB Gazyva inj 1,000 mg/40 mL inj50242007001Listed by the FDA as Gazyvaobinutuzumab1,000 mg/40 mLinjection, solution, concentrateGenentech, Inc. | 246,600.69 (Schedule G, line 37, page 11 of the filing PDF) | 47 |
| 38 | MPB Tavalisse 100 mg tab 6071332000101Listed by the FDA as Tavalissefostamatinib100 mgtabletRigel Pharmaceuticals, Inc. | 239,946.48 (Schedule G, line 38, page 11 of the filing PDF) | 29 |
| 39 | Stelara PFS 90 mg/1.0 mL 157894006103Listed by the FDA as Stelaraustekinumab90 mg/mLinjection, solutionJanssen Biotech, Inc. | 239,671.99 (Schedule G, line 39, page 11 of the filing PDF) | 29 |
| 40 | Mekinist tab 2 mg00078111215Listed by the FDA as Mekinisttrametinib2 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 238,145.26 (Schedule G, line 40, page 11 of the filing PDF) | 14 |
| 41 | Taltz 80 mg/mL autoinjector00002144511Listed by the FDA as Taltzixekizumab80 mg/mLinjection, solutionEli Lilly and Company | 237,833.62 (Schedule G, line 41, page 11 of the filing PDF) | 32 |
| 42 | Tafinlar 75 mg capsule00078068166Listed by the FDA as Tafinlardabrafenib75 mgcapsuleNovartis Pharmaceuticals Corporation | 234,586.59 (Schedule G, line 42, page 11 of the filing PDF) | 14 |
| 43 | Kisqali 600 mg Daily dose00078087463Listed by the FDA as Kisqaliribociclib200 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 229,674.19 (Schedule G, line 43, page 11 of the filing PDF) | 12 |
| 44 | Ozempic 0.25-0.5 mg/dose pen00169418113Listed by the FDA as Ozempicsemaglutide0.68 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 226,875.28 (Schedule G, line 44, page 11 of the filing PDF) | 701 |
| 45 | Mounjaro 7.5 mg/0.5 mL pen00002148480Listed by the FDA as Mounjarotirzepatide7.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 222,565.78 (Schedule G, line 45, page 11 of the filing PDF) | 18 |
| 46 | Ozempic 2 mg/dose (8 mg/3 mL)00169477212Listed by the FDA as Ozempicsemaglutide2.68 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 220,425.00 (Schedule G, line 46, page 11 of the filing PDF) | 820 |
| 47 | Mounjaro 2.5 mg/0.5 mL pen00002150680Listed by the FDA as Mounjarotirzepatide2.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 217,002.22 (Schedule G, line 47, page 11 of the filing PDF) | 15 |
| 48 | MPB Tecentriq 1,200 mg/20 mL SDV50242091701Listed by the FDA as Tecentriqatezolizumab1,200 mg/20 mLinjection, solutionGenentech, Inc. | 207,753.69 (Schedule G, line 48, page 11 of the filing PDF) | 27 |
| 49 | asciminib (Scemblix) 40 mg Tab00078109820Listed by the FDA as Scemblixasciminib40 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 206,269.52 (Schedule G, line 49, page 11 of the filing PDF) | 20 |
| 50 | Mounjaro 10 mg/0.5 mL pen00002147180Listed by the FDA as Mounjarotirzepatide10 mg/0.5 mLinjection, solutionEli Lilly and Company | 205,173.97 (Schedule G, line 50, page 11 of the filing PDF) | 23 |
| 51 | Ozempic 1 mg/dose (4 mg/3 mL)00169413013Listed by the FDA as Ozempicsemaglutide1.34 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 202,809.95 (Schedule G, line 51, page 11 of the filing PDF) | 562 |
| 52 | MPB Lonsurf 20 mg/8.19 mg tab 6064842102003Listed by the FDA as Lonsurftrifluridine and tipiracil20 mg; 8.19 mgtablet, film coatedTaiho Pharmaceutical Co., Ltd. | 200,790.95 (Schedule G, line 52, page 11 of the filing PDF) | 19 |
| 53 | MPB Tepmetko 225 mg tab 30 DS44087500003Listed by the FDA as Tepmetkotepotinib hydrochloride225 mgtabletEMD Serono, Inc. | 198,564.10 (Schedule G, line 53, page 11 of the filing PDF) | 21 |
| 54 | Verzenio 50 mg tablet00002448354Listed by the FDA as Verzenioabemaciclib50 mgtabletEli Lilly and Company | 197,159.48 (Schedule G, line 54, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 55 | MPB Jakafi 10 mg tab 6050881001060Listed by the FDA as Jakafiruxolitinib10 mgtabletIncyte Corporation | 196,312.46 (Schedule G, line 55, page 11 of the filing PDF) | 34 |
| 56 | Actemra ACTPen inj 162 mg/0.9 mL50242014301Listed by the FDA as Actemra ACTPentocilizumab162 mg/0.9 mLinjection, solutionGenentech, Inc. | 196,287.78 (Schedule G, line 56, page 11 of the filing PDF) | 100 |
| 57 | canakinumab (Ilaris, PF,) 150 mg/mL Soln00078073461Listed by the FDA as Ilariscanakinumab150 mg/mLinjection, solutionNovartis Pharmaceuticals Corporation | 194,196.84 (Schedule G, line 57, page 11 of the filing PDF) | 14 |
| 58 | Repatha 140 mg/mL Sureclick 2CT72511076002Listed by the FDA as Repathaevolocumab140 mg/mLinjection, solutionAmgen USA Inc. | 192,265.18 (Schedule G, line 58, page 12 of the filing PDF) | 1,118 |
| 59 | Bridion 200 mg/2 mL SOLN00006542312Listed by the FDA as Bridionsugammadex100 mg/mLinjection, solutionMerck Sharp & Dohme LLC | 192,125.48 (Schedule G, line 59, page 12 of the filing PDF) | 2,269 |
| 60 | MPB Sarclisa 500 mg/25 mL SDV00024065601Listed by the FDA as Sarclisaisatuximab500 mg/25 mLinjection, solution, concentrateSanofi-Aventis U.S. LLC | 188,067.09 (Schedule G, line 60, page 12 of the filing PDF) | 65 |
| 61 | Gammagard liquid 10% vial00944270007Listed by the FDA as Gammagard Liquidimmune globulin infusion (human)100 mg/mLinjection, solutionTakeda Pharmaceuticals America, Inc. | 186,216.80 (Schedule G, line 61, page 12 of the filing PDF) | 119 |
| 62 | osimertinib (Tagrisso) 40 mg Tab00310134930Listed by the FDA as Tagrissoosimertinib40 mgtablet, film coatedAstraZeneca Pharmaceuticals LP | 180,379.65 (Schedule G, line 62, page 12 of the filing PDF) | 14 |
| 63 | MPB Reblozyl 75 mg SDV59572077501Listed by the FDA as Reblozylluspatercept75 mginjection, powder, lyophilized, for solutionCelgene Corporation | 170,509.02 (Schedule G, line 63, page 12 of the filing PDF) | 19 |
| 64 | glecaprevir-pibrentasvir (Mavyret) 100-40 mg Tab00074262528Listed by the FDA as Mavyretglecaprevir and pibrentasvir40 mg; 100 mgtablet, film coatedAbbVie Inc. | 169,321.81 (Schedule G, line 64, page 12 of the filing PDF) | 9 |
| 65 | Mounjaro 15 mg/0.5 mL pen00002145780Listed by the FDA as Mounjarotirzepatide15 mg/0.5 mLinjection, solutionEli Lilly and Company | 168,293.50 (Schedule G, line 65, page 12 of the filing PDF) | 10 |
| 66 | Kevzara inj PFP200 mg/1.14 mL 200024592201Listed by the FDA as Kevzarasarilumab200 mg/1.14 mLinjection, solutionSanofi-Aventis U.S. LLC | 166,932.87 (Schedule G, line 66, page 12 of the filing PDF) | 88 |
| 67 | Trelegy Ellipta 200-62.5-2500173089310Listed by the FDA as Trelegy Elliptafluticasone furoate, umeclidinium bromide and vilanterol trifenatate200 mcg; 62.5 mcg; 25 mcgpowderGlaxoSmithKline LLC | 163,642.98 (Schedule G, line 67, page 12 of the filing PDF) | 675 |
| 68 | MPB Imbruvica 420 mg tab 2857962042028Listed by the FDA as Imbruvicaibrutinib420 mgtablet, film coatedPharmacyclics LLC | 154,896.66 (Schedule G, line 68, page 12 of the filing PDF) | 24 |
| 69 | MPB Jakafi 20 mg tab 6050881002060Listed by the FDA as Jakafiruxolitinib20 mgtabletIncyte Corporation | 150,533.78 (Schedule G, line 69, page 12 of the filing PDF) | 26 |
| 70 | midostaurin (Rydapt) 25 mg cap00078069819Listed by the FDA as Rydapt25 mgcapsule, liquid filledNovartis Pharmaceuticals Corporation | 149,632.24 (Schedule G, line 70, page 12 of the filing PDF) | 6 |
| 71 | Ibrance 100 mg tablet00069048603Listed by the FDA as Ibrancepalbociclib100 mgtablet, film coatedPfizer Laboratories Div Pfizer Inc | 149,033.77 (Schedule G, line 71, page 12 of the filing PDF) | 18 |
| 72 | enzalutamide 40 mg cap00469012599Listed by the FDA as Xtandienzalutamide40 mgcapsuleAstellas Pharma US, Inc. | 148,991.78 (Schedule G, line 72, page 12 of the filing PDF) | 13 |
| 73 | nilotinib HCl 150 mg cap00078059287Listed by the FDA as Tasignanilotinib150 mgcapsuleNovartis Pharmaceuticals Corporation | 148,606.03 (Schedule G, line 73, page 12 of the filing PDF) | 26 |
| 74 | Rinvoq ER 15 mg tablet00074230630Listed by the FDA as Rinvoqupadacitinib15 mgtablet, extended releaseAbbVie Inc. | 141,029.85 (Schedule G, line 74, page 12 of the filing PDF) | 52 |
| 75 | MPB Doptelet 20 mg tab 1571369002015Listed by the FDA as Dopteletavatrombopag maleate20 mgtablet, film coatedAkaRx, Inc. | 140,431.86 (Schedule G, line 75, page 12 of the filing PDF) | 37 |
| 76 | MPB Vonjo 100 mg cap 12072482010012Listed by the FDA as Vonjopacritinib100 mgcapsuleSobi, Inc. | 137,892.12 (Schedule G, line 76, page 12 of the filing PDF) | 9 |
| 77 | cabazitaxel 60 mg/6 mL INJ00024582411Listed by the FDA as JevtanacabazitaxelkitSanofi-Aventis U.S. LLC | 135,477.92 (Schedule G, line 77, page 12 of the filing PDF) | 23 |
| 78 | MPB Lonsurf 15 mg/6.14 mg tab 6064842102503Listed by the FDA as Lonsurftrifluridine and tipiracil15 mg; 6.14 mgtablet, film coatedTaiho Pharmaceutical Co., Ltd. | 134,817.20 (Schedule G, line 78, page 12 of the filing PDF) | 17 |
| 79 | iron dextran 100 mg/2 mL INJ00023608210Listed by the FDA as INFeDiron dextran50 mg/mLinjectionAllergan, Inc. | 133,832.32 (Schedule G, line 79, page 12 of the filing PDF) | 358 |
| 80 | MPB Brukinsa 160 mg tab 6072579012201Listed by the FDA as Brukinsazanubrutinib160 mgtablet, film coatedBeOne Medicines USA, Inc. | 133,178.54 (Schedule G, line 80, page 12 of the filing PDF) | 11 |
| 81 | Trelegy Ellipta 100-62.5-2500173088710Listed by the FDA as Trelegy Elliptafluticasone furoate, umeclidinium bromide and vilanterol trifenatate100 mcg; 62.5 mcg; 25 mcgpowderGlaxoSmithKline LLC | 128,672.64 (Schedule G, line 81, page 12 of the filing PDF) | 789 |
| 82 | ribociclib (Kisqali) 400 mg/day (200 mg x 2) Tab00078086742Listed by the FDA as Kisqaliribociclib200 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 127,830.02 (Schedule G, line 82, page 12 of the filing PDF) | 16 |
| 83 | Hadlima PSH inj 40 mg/0.4 mL 2PK78206018701Listed by the FDA as Hadlimaadalimumab-bwwd40 mg/0.4 mLsolutionOrganon LLC | 127,026.66 (Schedule G, line 83, page 12 of the filing PDF) | 218 |
| 84 | MPB Kyprolis 60 mg inj pwd76075010101Listed by the FDA as Kyproliscarfilzomib60 mg/30 mLinjection, powder, lyophilized, for solutionOnyx Pharmaceuticals, Inc. | 126,559.70 (Schedule G, line 84, page 12 of the filing PDF) | 82 |
| 85 | Nplate 500 mcg SOLR55513022201Listed by the FDA as Nplateromiplostim500 mcg/mLinjection, powder, lyophilized, for solutionAmgen, Inc | 122,752.37 (Schedule G, line 85, page 12 of the filing PDF) | 148 |
| 86 | MPB Lenvima 18 mg BPK cap 9062856071830Listed by the FDA as LenvimalenvatinibkitEisai Inc. | 120,481.41 (Schedule G, line 86, page 12 of the filing PDF) | 11 |
| 87 | Repatha LF inj 140 mg 1 mL 272511039302Listed by the FDA as Repathaevolocumab140 mg/mLinjection, solutionAmgen USA Inc. | 119,366.36 (Schedule G, line 87, page 12 of the filing PDF) | 697 |
| 88 | MPB Enhertu 100 mg SDV65597040601Listed by the FDA as Enhertufam-trastuzumab deruxtecan-nxki100 mg/5 mLinjection, powder, lyophilized, for solutionDaiichi Sankyo Inc. | 117,375.84 (Schedule G, line 88, page 12 of the filing PDF) | 56 |
| 89 | Xgeva SDV 120 mg/1.7 mL 155513073001Listed by the FDA as Xgevadenosumab120 mg/1.7 mLinjectionAmgen, Inc | 116,922.90 (Schedule G, line 89, page 12 of the filing PDF) | 78 |
| 90 | MPB Polivy 30 mg SDV50242010301Listed by the FDA as Polivypolatuzumab vedotin30 mg/1.88 mLinjection, powder, lyophilized, for solutionGenentech, Inc. | 116,002.13 (Schedule G, line 90, page 12 of the filing PDF) | 40 |
| 91 | Trulicity 3 mg/0.5 mL pen00002223680Listed by the FDA as Trulicitydulaglutide3 mg/0.5 mLinjection, solutionEli Lilly and Company | 113,433.21 (Schedule G, line 91, page 12 of the filing PDF) | 6 |
| 92 | MPB Yervoy 50 mg/10 mL SDV00003232711Listed by the FDA as Yervoyipilimumab5 mg/mLinjectionE.R. Squibb & Sons, L.L.C. | 112,974.18 (Schedule G, line 92, page 12 of the filing PDF) | 18 |
| 93 | Dupixent PFS300 mg/2 mL 200024591401Listed by the FDA as Dupixentdupilumab300 mg/2 mLinjection, solutionSanofi-Aventis U.S. LLC | 109,947.01 (Schedule G, line 93, page 12 of the filing PDF) | 50 |
| 94 | Zepbound 5 mg/0.5 mL pen00002249580Listed by the FDA as Zepboundtirzepatide5 mg/0.5 mLinjection, solutionEli Lilly and Company | 109,749.40 (Schedule G, line 94, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 95 | MPB Lazcluze 80 mg tab 6057894008060Listed by the FDA as Lazcluzelazertinib80 mgtablet, film coatedJanssen Biotech, Inc. | 109,267.39 (Schedule G, line 95, page 12 of the filing PDF) | 8 |
| 96 | capmatinib 200 mg Tab00078071656Listed by the FDA as Tabrectacapmatinib200 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 107,217.18 (Schedule G, line 96, page 13 of the filing PDF) | 7 |
| 97 | MPB Sarclisa 100 mg/5 mL SDV00024065401Listed by the FDA as Sarclisaisatuximab100 mg/5 mLinjection, solution, concentrateSanofi-Aventis U.S. LLC | 103,855.34 (Schedule G, line 97, page 13 of the filing PDF) | 180 |
| 98 | BESREMi 500 mcg/mL syringe73536050001Listed by the FDA as BESREMiropeginterferon alfa-2b500 mcg/mLinjectionPharmaEssentia USA | 103,686.65 (Schedule G, line 98, page 13 of the filing PDF) | 37 |
| 99 | momelotinib (Ojjaara) 100 mg Tab81864010330Listed by the FDA as Ojjaaramomelotinib100 mgtabletGlaxoSmithKline LLC | 103,634.09 (Schedule G, line 99, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 100 | Eliquis 5 mg tablet00003089421Listed by the FDA as Eliquisapixaban5 mgtablet, film coatedE.R. Squibb & Sons, L.L.C. | 103,028.64 (Schedule G, line 100, page 13 of the filing PDF) | 2,377 |
| 101 | Zepbound 2.5 mg/0.5 mL inj (4PF pens)00002250680Listed by the FDA as Zepboundtirzepatide2.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 100,133.22 (Schedule G, line 101, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 102 | Trulicity 4.5 mg/0.5 mL pen00002318280Listed by the FDA as Trulicitydulaglutide4.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 99,808.57 (Schedule G, line 102, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 103 | Ruxience 500 mg/50 mL SOLN00069024901Listed by the FDA as Ruxiencerituximab-pvvr500 mg/50 mLinjection, solutionPfizer Laboratories Div Pfizer Inc | 99,734.08 (Schedule G, line 103, page 13 of the filing PDF) | 224 |
| 104 | MPB Jaypirca 100 mg tab 6000002702660Listed by the FDA as Jaypircapirtobrutinib100 mgtablet, coatedEli Lilly and Company | 99,586.02 (Schedule G, line 104, page 13 of the filing PDF) | 6 |
| 105 | Privigen 10 g/100 mL SOLN44206043710Listed by the FDA as Privigenhuman immunoglobulin G10 g/100 mLliquidCSL Behring AG | 97,655.46 (Schedule G, line 105, page 13 of the filing PDF) | 160 |
| 106 | MPB Benlysta SC pen 200 mg/mL 449401008835Listed by the FDA as Benlystabelimumab200 mg/mLsolutionGlaxoSmithKline LLC | 96,918.95 (Schedule G, line 106, page 13 of the filing PDF) | 29 |
| 107 | Botox 200 units SOLR00023392102Listed by the FDA as BotoxonabotulinumtoxinA200 USP unitsinjection, powder, lyophilized, for solutionAllergan, Inc. | 95,408.07 (Schedule G, line 107, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 108 | Dupixent 200 mg/1.14 mL pen00024591902Listed by the FDA as Dupixentdupilumab200 mg/1.14 mLinjection, solutionSanofi-Aventis U.S. LLC | 95,245.85 (Schedule G, line 108, page 13 of the filing PDF) | 15 |
| 109 | Teriparatide inj 250 mcg/mL 147781065289Listed by the FDA as Teriparatide250 mcg/mLinjection, solutionAlvogen, Inc. | 92,833.00 (Schedule G, line 109, page 13 of the filing PDF) | 25 |
| 110 | immune globulin (Gammagard) IV 10% 20 g/200 mL00944270006Listed by the FDA as Gammagard Liquidimmune globulin infusion (human)100 mg/mLinjection, solutionTakeda Pharmaceuticals America, Inc. | 91,936.40 (Schedule G, line 110, page 13 of the filing PDF) | 60 |
| 111 | MPB Tavalisse 150 mg tab 6071332000201Listed by the FDA as Tavalissefostamatinib150 mgtabletRigel Pharmaceuticals, Inc. | 91,402.43 (Schedule G, line 111, page 13 of the filing PDF) | 11 |
| 112 | Mounjaro 12.5 mg/0.5 mL pen00002146080Listed by the FDA as Mounjarotirzepatide12.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 90,438.58 (Schedule G, line 112, page 13 of the filing PDF) | 6 |
| 113 | MPB Imbruvica 140 mg cap 90S57962014009Listed by the FDA as Imbruvicaibrutinib140 mgcapsulePharmacyclics LLC | 90,138.54 (Schedule G, line 113, page 13 of the filing PDF) | 13 |
| 114 | Pomalyst 3 mg capsule59572050321Listed by the FDA as Pomalystpomalidomide3 mgcapsuleCelgene Corporation | 89,061.64 (Schedule G, line 114, page 13 of the filing PDF) | 10 |
| 115 | Nucala inj 100 mg/mL00173089242Listed by the FDA as Nucalamepolizumab100 mg/mLinjection, solutionGlaxoSmithKline LLC | 88,510.68 (Schedule G, line 115, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 116 | Rinvoq ER 30 mg tablet00074231030Listed by the FDA as Rinvoqupadacitinib30 mgtablet, extended releaseAbbVie Inc. | 88,166.23 (Schedule G, line 116, page 13 of the filing PDF) | 35 |
| 117 | Tremfya 100 mg 157894064011Listed by the FDA as Tremfyaguselkumab100 mg/mLinjectionJanssen Biotech, Inc. | 81,635.98 (Schedule G, line 117, page 13 of the filing PDF) | 20 |
| 118 | MPB Krazati 200 mg tab 18080739081218Listed by the FDA as Krazatiadagrasib200 mgtablet, coatedMirati Therapeutics, Inc | 78,447.08 (Schedule G, line 118, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 119 | olaparib (Lynparza) 150 mg Tab00310067912Listed by the FDA as Lynparzaolaparib150 mgtablet, film coatedAstraZeneca Pharmaceuticals LP | 78,210.90 (Schedule G, line 119, page 13 of the filing PDF) | 7 |
| 120 | MPB Kadcyla 160 mg SDV50242008701Listed by the FDA as Kadcylaado-trastuzumab emtansine20 mg/mLinjection, powder, lyophilized, for solutionGenentech, Inc. | 76,928.74 (Schedule G, line 120, page 13 of the filing PDF) | 17 |
| 121 | ribociclib (Kisqali) 200 mg/day (200 mg x 1) Tab00078086001Listed by the FDA as Kisqaliribociclib200 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 76,772.60 (Schedule G, line 121, page 13 of the filing PDF) | 18 |
| 122 | Trulicity 1.5 mg/0.5 mL pen00002143480Listed by the FDA as Trulicitydulaglutide1.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 76,729.91 (Schedule G, line 122, page 13 of the filing PDF) | 17 |
| 123 | MPB Lenvima 10 mg BPK cap 3062856071030Listed by the FDA as Lenvimalenvatinib10 mgcapsuleEisai Inc. | 76,718.04 (Schedule G, line 123, page 13 of the filing PDF) | 7 |
| 124 | Shingrix SDV 50 mcg 0.5 mL 1058160082311Listed by the FDA as Shingrixzoster vaccine recombinant, adjuvantedkitGlaxoSmithKline Biologicals SA | 75,681.19 (Schedule G, line 124, page 13 of the filing PDF) | 39 |
| 125 | MPB Jakafi 15 mg tab 6050881001560Listed by the FDA as Jakafiruxolitinib15 mgtabletIncyte Corporation | 74,926.48 (Schedule G, line 125, page 13 of the filing PDF) | 13 |
| 126 | MPB Alunbrig 180 mg tab 30CT63020018030Listed by the FDA as Alunbrigbrigatinib180 mgtablet, film coatedTakeda Pharmaceuticals America, Inc. | 73,273.87 (Schedule G, line 126, page 13 of the filing PDF) | 13 |
| 127 | MPB Alecensa 150 mg cap 24050242013001Listed by the FDA as Alecensaalectinib hydrochloride150 mgcapsuleGenentech, Inc. | 73,176.55 (Schedule G, line 127, page 13 of the filing PDF) | 6 |
| 128 | Entresto 24 mg-26 mg tablet00078065920Listed by the FDA as Entrestosacubitril and valsartan24 mg; 26 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 72,489.30 (Schedule G, line 128, page 13 of the filing PDF) | 437 |
| 129 | (no name printed)secukinumab (Cosentyx UnoReady Pen) 300 mg/2 mL PnIj00078107068 | 71,121.33 (Schedule G, line 129, page 13 of the filing PDF) | 29 |
| 130 | Invega Sustenna 234 mg kit50458056401Listed by the FDA as Invega Sustennapaliperidone palmitate234 mg/1.5 mLinjectionJanssen Pharmaceuticals, Inc. | 71,043.83 (Schedule G, line 130, page 13 of the filing PDF) | 60 |
| 131 | MPB Mektovi 15 mg tab 18070255001002Listed by the FDA as Mektovibinimetinib15 mgtablet, film coatedArray BioPharma Inc. | 70,095.64 (Schedule G, line 131, page 13 of the filing PDF) | 7 |
| 132 | Vivitrol 380 mg SUSR65757030001Listed by the FDA as VivitrolnaltrexonekitAlkermes, Inc. | 69,790.54 (Schedule G, line 132, page 13 of the filing PDF) | 101 |
| 133 | MPB Braftovi 75 mg cap 90x270255002501Listed by the FDA as Braftoviencorafenib75 mgcapsuleArray BioPharma Inc. | 69,467.86 (Schedule G, line 133, page 13 of the filing PDF) | 8 |
| 134 | MPB Mekinist 0.5 mg tab 3000078110515Listed by the FDA as Mekinisttrametinib0.5 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 69,328.24 (Schedule G, line 134, page 14 of the filing PDF) | 38 |
| 135 | Dupixent 200 mg/1.14 mL Syring00024591801Listed by the FDA as Dupixentdupilumab200 mg/1.14 mLinjection, solutionSanofi-Aventis U.S. LLC | 69,140.60 (Schedule G, line 135, page 14 of the filing PDF) | 13 |
| 136 | MPB Lazcluze 240 mg tab 3057894024030Listed by the FDA as Lazcluzelazertinib240 mgtablet, film coatedJanssen Biotech, Inc. | 68,986.01 (Schedule G, line 136, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 137 | MPB Polivy 140 mg SDV50242010501Listed by the FDA as Polivypolatuzumab vedotin140 mg/7.52 mLinjection, powder, lyophilized, for solutionGenentech, Inc. | 68,654.59 (Schedule G, line 137, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 138 | MPB Lenvima 8 mg BPK cap 6062856070830Listed by the FDA as Lenvimalenvatinib4 mgcapsuleEisai Inc. | 66,005.92 (Schedule G, line 138, page 14 of the filing PDF) | 6 |
| 139 | MPB Reblozyl 25 mg SDV59572071101Listed by the FDA as Reblozylluspatercept25 mginjection, powder, lyophilized, for solutionCelgene Corporation | 65,831.69 (Schedule G, line 139, page 14 of the filing PDF) | 22 |
| 140 | MPB Lenvima 20 mg BPK cap 6062856072030Listed by the FDA as Lenvimalenvatinib10 mgcapsuleEisai Inc. | 64,449.09 (Schedule G, line 140, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 141 | MPB Soliris 10 mg/mL30 mL SDV DS25682000101Listed by the FDA as Soliriseculizumab300 mg/30 mLinjection, solution, concentrateAlexion Pharmaceuticals Inc. | 63,379.03 (Schedule G, line 141, page 14 of the filing PDF) | 13 |
| 142 | MPB Esbriet 801 mg tab 9050242012301Listed by the FDA as Esbrietpirfenidone801 mgtablet, coatedGenentech, Inc. | 62,538.08 (Schedule G, line 142, page 14 of the filing PDF) | 8 |
| 143 | MPB Ojjaara 200 mg tab 3081864010130Listed by the FDA as Ojjaaramomelotinib200 mgtabletGlaxoSmithKline LLC | 62,120.57 (Schedule G, line 143, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 144 | tremelimumab-actl 300 mg in sodium chloride 0.9% 100 mL chemo IVPB00310453530Listed by the FDA as Imjudotremelimumab300 mg/15 mLinjection, solutionAstraZeneca Pharmaceuticals LP | 60,842.00 (Schedule G, line 144, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 145 | capmatinib 150 mg Tab00078070956Listed by the FDA as Tabrectacapmatinib150 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 60,774.23 (Schedule G, line 145, page 14 of the filing PDF) | 6 |
| 146 | MPB Stivarga 40 mg tab 21 CT450419017106Listed by the FDA as Stivargaregorafenib40 mgtablet, film coatedBayer HealthCare Pharmaceuticals Inc. | 59,914.88 (Schedule G, line 146, page 14 of the filing PDF) | 8 |
| 147 | Zepbound 7.5 mg/0.5 mL x 4PEND AM00002248480Listed by the FDA as Zepboundtirzepatide7.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 58,864.40 (Schedule G, line 147, page 14 of the filing PDF) | 74 |
| 148 | Inlyta tab 5 mg00069015111Listed by the FDA as Inlytaaxitinib5 mgtablet, film coatedPfizer Laboratories Div Pfizer Inc | 58,027.99 (Schedule G, line 148, page 14 of the filing PDF) | 8 |
| 149 | Bendeka MDV 100 mg 4 mL63459034804Listed by the FDA as Bendekabendamustine hydrochloride25 mg/mLinjection, solutionTeva Pharmaceuticals USA, Inc. | 57,919.66 (Schedule G, line 149, page 14 of the filing PDF) | 75 |
| 150 | Bosulif 100 mg tablet00069013501Listed by the FDA as Bosulifbosutinib100 mgtablet, film coatedPfizer Laboratories Div Pfizer Inc | 57,324.41 (Schedule G, line 150, page 14 of the filing PDF) | 14 |
| 151 | octreotide LAR 20 mg PWDI00078081881Listed by the FDA as Sandostatin LAR Depotoctreotide acetatekitNovartis Pharmaceuticals Corporation | 56,665.27 (Schedule G, line 151, page 14 of the filing PDF) | 78 |
| 152 | MPB Inrebic 100 mg cap 12059572072012Listed by the FDA as Inrebicfedratinib hydrochloride100 mgcapsuleCelgene Corporation | 55,910.84 (Schedule G, line 152, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 153 | siponimod (Mayzent) 2 mg Tab00078098615Listed by the FDA as Mayzentsiponimod2 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 55,654.31 (Schedule G, line 153, page 14 of the filing PDF) | 9 |
| 154 | nivolumab 40 mg/4 mL INJ00003377211Listed by the FDA as Opdivonivolumab10 mg/mLinjectionE.R. Squibb & Sons, L.L.C. | 54,644.18 (Schedule G, line 154, page 14 of the filing PDF) | 24 |
| 155 | Basaglar KwikPen 3 mL 500002771559Listed by the FDA as Basaglar KwikPeninsulin glargine100 IU/mLinjection, solutionEli Lilly and Company | 54,287.20 (Schedule G, line 155, page 14 of the filing PDF) | 240 |
| 156 | MPB Orgovyx 120 mg tab 3072974012001Listed by the FDA as Orgovyxrelugolix120 mgtablet, film coatedSumitomo Pharma America, Inc. | 52,991.22 (Schedule G, line 156, page 14 of the filing PDF) | 28 |
| 157 | Wegovy 2.4 mg/0.75 mL pen00169452414Listed by the FDA as Wegovysemaglutide2.4 mg/0.75 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 51,602.85 (Schedule G, line 157, page 14 of the filing PDF) | 86 |
| 158 | HyperRAB 1,500 units/5 mL SOLN13533031805Listed by the FDA as HyperRABrabies immune globulin (human)300 IU/mLinjection, solutionGrifols USA, LLC | 51,455.68 (Schedule G, line 158, page 14 of the filing PDF) | 30 |
| 159 | MPB Monjuvi 200 mg SDV50881001303Listed by the FDA as Monjuvitafasitamab-cxix200 mg/5 mLinjection, powder, lyophilized, for solutionIncyte Corporation | 51,328.50 (Schedule G, line 159, page 14 of the filing PDF) | 50 |
| 160 | Breztri Aerosphere inhaler00310461612Listed by the FDA as Breztribudesonide, glycopyrrolate, and formoterol fumarate160 mcg; 9 mcg; 4.8 mcgaerosol, meteredAstraZeneca Pharmaceuticals LP | 51,036.19 (Schedule G, line 160, page 14 of the filing PDF) | 235 |
| 161 | MPB Ocrevus 300 mg/10 mL SDV50242015001Listed by the FDA as Ocrevusocrelizumab300 mg/10 mLinjectionGenentech, Inc. | 50,978.22 (Schedule G, line 161, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 162 | MPB Octagam 10% 20 g/200 mL68982085004Listed by the FDA as Octagam Immune Globulin (Human)immune globulin100 mg/mLsolutionOctapharma USA Inc | 49,454.95 (Schedule G, line 162, page 14 of the filing PDF) | 38 |
| 163 | MPB Phesgo 1,200 mg/10 mL SDV kit50242026001Listed by the FDA as Phesgopertuzumab, trastuzumab, and hyaluronidase-zzxf600 mg/10 mL; 600 mg/10 mL; 20,000 units/10 mLinjection, solutionGenentech, Inc. | 49,387.50 (Schedule G, line 163, page 14 of the filing PDF) | 10 |
| 164 | Tyenne auto inj 162 mg/0.9 mL 165219058401Listed by the FDA as Tyennetocilizumab-aazg162 mg/0.9 mLinjection, solutionFresenius Kabi USA, LLC | 49,093.88 (Schedule G, line 164, page 14 of the filing PDF) | 120 |
| 165 | Zepbound 10 mg/0.5 mL pen00002247180Listed by the FDA as Zepboundtirzepatide10 mg/0.5 mLinjection, solutionEli Lilly and Company | 48,801.95 (Schedule G, line 165, page 14 of the filing PDF) | 7 |
| 166 | MPB Kadcyla 100 mg SDV50242008801Listed by the FDA as Kadcylaado-trastuzumab emtansine20 mg/mLinjection, powder, lyophilized, for solutionGenentech, Inc. | 48,089.31 (Schedule G, line 166, page 14 of the filing PDF) | 17 |
| 167 | Durolane 60 mg/3 mL PRSY89130202001 | 48,005.86 (Schedule G, line 167, page 14 of the filing PDF) | 41 |
| 168 | MPB Idhifa 100 mg tab 3059572071030Listed by the FDA as Idhifaenasidenib mesylate100 mgtablet, film coatedCelgene Corporation | 46,515.58 (Schedule G, line 168, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 169 | semaglutide, weight loss, (Wegovy) 0.25 mg/0.5 mL pen-injector00169452514Listed by the FDA as Wegovysemaglutide0.25 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 45,223.35 (Schedule G, line 169, page 14 of the filing PDF) | 81 |
| 170 | MPB Enjaymo 1,100 mg/22 mL SDV55292082001Listed by the FDA as Enjaymosutimlimab-jome50 mg/mLinjection, solution, concentrateRecordati Rare Diseases, Inc. | 45,205.20 (Schedule G, line 170, page 14 of the filing PDF) | 30 |
| 171 | MPB Inqovi 35 mg/100 mg tab 564842072709Listed by the FDA as Inqovicedazuridine and decitabine100 mg; 35 mgtablet, film coatedTaiho Pharmaceutical Co., Ltd. | 45,120.56 (Schedule G, line 171, page 14 of the filing PDF) | 7 |
| 172 | Xifaxan tab 550 mg 6065649030302Listed by the FDA as Xifaxanrifaximin550 mgtabletSalix Pharmaceuticals, Inc. | 45,001.08 (Schedule G, line 172, page 15 of the filing PDF) | 65 |
| 173 | Botox 100 units vial00023114501Listed by the FDA as BotoxonabotulinumtoxinA100 USP unitsinjection, powder, lyophilized, for solutionAllergan, Inc. | 44,857.60 (Schedule G, line 173, page 15 of the filing PDF) | 86 |
| 174 | Bosulif 500 mg tablet00069013601Listed by the FDA as Bosulifbosutinib500 mgtablet, film coatedPfizer Laboratories Div Pfizer Inc | 44,825.91 (Schedule G, line 174, page 15 of the filing PDF) | 12 |
| 175 | Dovato TB 50/300 mg 3049702024613Listed by the FDA as Dovatodolutegravir sodium and lamivudine50 mg; 300 mgtablet, film coatedViiV Healthcare Company | 44,139.63 (Schedule G, line 175, page 15 of the filing PDF) | 23 |
| 176 | semaglutide, weight loss, (Wegovy) 1.7 mg/0.75 mL pen-injector00169451714Listed by the FDA as Wegovysemaglutide1.7 mg/0.75 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 43,158.06 (Schedule G, line 176, page 15 of the filing PDF) | 71 |
| 177 | MPB Fotivda 0.89 mg caps 2145629008902Listed by the FDA as Fotivdativozanib0.89 mgcapsuleAVEO Pharmaceuticals, Inc. | 42,752.70 (Schedule G, line 177, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 178 | MPB Fotivda 0.89 mg caps 2145629008901Listed by the FDA as Fotivdativozanib0.89 mgcapsuleAVEO Pharmaceuticals, Inc.the product is listed, not this package | 42,219.70 (Schedule G, line 178, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 179 | Orencia Clickject 125 mg/mL00003218851Listed by the FDA as Orenciaabatacept125 mg/mLinjection, solutionE.R. Squibb & Sons, L.L.C. | 42,076.33 (Schedule G, line 179, page 15 of the filing PDF) | 36 |
| 180 | TNKase 50 mg KIT50242012047Listed by the FDA as TNKasetenecteplasekitGenentech, Inc. | 41,341.36 (Schedule G, line 180, page 15 of the filing PDF) | 40 |
| 181 | Trulicity 0.75 mg/0.5 mL pen 400002143380Listed by the FDA as Trulicitydulaglutide0.75 mg/0.5 mLinjection, solutionEli Lilly and Company | 40,755.43 (Schedule G, line 181, page 15 of the filing PDF) | 112 |
| 182 | Cosentyx Sensoready 150 mg pen00078063968Listed by the FDA as Cosentyxsecukinumab150 mg/mLinjectionNovartis Pharmaceuticals Corporation | 40,470.19 (Schedule G, line 182, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 183 | Zepbound 12.5 mg/0.5 mL pen00002246080Listed by the FDA as Zepboundtirzepatide12.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 39,719.49 (Schedule G, line 183, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 184 | Abilify Maintena ER 400 mg kit59148024512Listed by the FDA as Abilify MaintenaaripiprazolekitOtsuka America Pharmaceutical, Inc. | 39,709.41 (Schedule G, line 184, page 15 of the filing PDF) | 27 |
| 185 | Kcentra 500 units KIT63833038602Listed by the FDA as Kcentraprothrombin, coagulation factor VII human, coagulation factor IX human, coagulation factor X human, protein C, protein S human, and waterkitCSL Behring GmbH | 39,536.42 (Schedule G, line 185, page 15 of the filing PDF) | 52 |
| 186 | MPB Empliciti 300 mg vial00003229111Listed by the FDA as Emplicitielotuzumab300 mginjection, powder, lyophilized, for solutionE.R. Squibb & Sons, L.L.C. | 38,960.48 (Schedule G, line 186, page 15 of the filing PDF) | 23 |
| 187 | Zepbound 15 mg/0.5 mL pen00002245780Listed by the FDA as Zepboundtirzepatide15 mg/0.5 mLinjection, solutionEli Lilly and Company | 38,932.39 (Schedule G, line 187, page 15 of the filing PDF) | 6 |
| 188 | Stelara PFS 45 mg/0.5 mL 157894006003Listed by the FDA as Stelaraustekinumab45 mg/0.5 mLinjection, solutionJanssen Biotech, Inc. | 38,715.02 (Schedule G, line 188, page 15 of the filing PDF) | 10 |
| 189 | olaparib (Lynparza) 100 mg Tab00310066812Listed by the FDA as Lynparzaolaparib100 mgtablet, film coatedAstraZeneca Pharmaceuticals LP | 38,397.12 (Schedule G, line 189, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 190 | semaglutide, weight loss, (Wegovy) 1 mg/0.5 mL pen-injector00169450114Listed by the FDA as Wegovysemaglutide1 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 37,902.64 (Schedule G, line 190, page 15 of the filing PDF) | 71 |
| 191 | Prolia 60 mg/mL SOSY55513071021Listed by the FDA as Proliadenosumab60 mg/mLinjectionAmgen, Inc | 37,444.18 (Schedule G, line 191, page 15 of the filing PDF) | 67 |
| 192 | Verzenio 200 mg tablet00002621654Listed by the FDA as Verzenioabemaciclib200 mgtabletEli Lilly and Company | 37,386.50 (Schedule G, line 192, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 193 | MPB Ilumya 100 mg/1 mL PFS47335017795Listed by the FDA as Ilumyatildrakizumab-asmn100 mg/mLinjection, solutionSun Pharmaceutical Industries, Inc. | 37,334.02 (Schedule G, line 193, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 194 | Brilinta 90 mg tablet00186077760Listed by the FDA as Brilintaticagrelor90 mgtabletAstraZeneca Pharmaceuticals LP | 37,212.56 (Schedule G, line 194, page 15 of the filing PDF) | 72 |
| 195 | Eliquis 2.5 mg tablet00003089321Listed by the FDA as Eliquisapixaban2.5 mgtablet, film coatedE.R. Squibb & Sons, L.L.C. | 37,052.13 (Schedule G, line 195, page 15 of the filing PDF) | 472 |
| 196 | Simlandi 40 mg/0.4 mL AI 251759040202Listed by the FDA as Simlandiadalimumab-ryvkkitTeva Pharmaceuticals USA, Inc. | 37,044.00 (Schedule G, line 196, page 15 of the filing PDF) | 72 |
| 197 | Dapagliflozin Propanediol 10 mg TABS66993045730Listed by the FDA as Dapagliflozin10 mgtablet, film coatedPrasco Laboratories | 36,621.73 (Schedule G, line 197, page 15 of the filing PDF) | 230 |
| 198 | Nurtec ODT 75 mg 872618300002Listed by the FDA as Nurtec ODTrimegepant sulfate75 mgtablet, orally disintegratingPfizer Laboratories Div Pfizer Inc | 36,607.72 (Schedule G, line 198, page 15 of the filing PDF) | 137 |
| 199 | Adalimumab-adaz pen 40 mg/0.4 mL61314032720Listed by the FDA as Adalimumabadalimumab-adaz40 mg/0.4 mLinjection, solutionSandoz Inc | 35,990.04 (Schedule G, line 199, page 15 of the filing PDF) | 66 |
| 200 | MPB Braftovi 75 mg cap 60x270255002503Listed by the FDA as Braftoviencorafenib75 mgcapsuleArray BioPharma Inc. | 35,935.40 (Schedule G, line 200, page 15 of the filing PDF) | 6 |
| 201 | capivasertib (Truqap) 200 mg tablet00310950101Listed by the FDA as Truqapcapivasertib200 mgtablet, film coatedAstraZeneca Pharmaceuticals LP | 35,310.22 (Schedule G, line 201, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 202 | MPB Cabometyx 20 mg tab 3042388002446Listed by the FDA as Cabometyxcabozantinib20 mgtabletExelixis, Inc. | 35,064.66 (Schedule G, line 202, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 203 | MPB Gamunex-C 10 g/100 mL13533080071Listed by the FDA as Gamunex-Cimmune globulin (human)10 g/100 mLinjectionGrifols USA, LLC | 34,055.84 (Schedule G, line 203, page 15 of the filing PDF) | 52 |
| 204 | Acetaminophen 10 mg/mL SOLN63323043400Listed by the FDA as Acetaminophen10 mg/mLinjectionFresenius Kabi USA, LLC | 33,972.62 (Schedule G, line 204, page 15 of the filing PDF) | 10,589 |
| 205 | MPB Benlysta SC PFS 200 mg/mL 449401008847Listed by the FDA as Benlystabelimumab200 mg/mLsolutionGlaxoSmithKline LLC | 33,343.91 (Schedule G, line 205, page 15 of the filing PDF) | 10 |
| 206 | Ruxience 100 mg/10 mL SOLN00069023801Listed by the FDA as Ruxiencerituximab-pvvr100 mg/10 mLinjection, solutionPfizer Laboratories Div Pfizer Inc | 33,118.08 (Schedule G, line 206, page 15 of the filing PDF) | 170 |
| 207 | Kevzara PFS 200 mg/1.14 mL 200024591001Listed by the FDA as Kevzarasarilumab200 mg/1.14 mLinjection, solutionSanofi-Aventis U.S. LLC | 32,166.93 (Schedule G, line 207, page 15 of the filing PDF) | 17 |
| 208 | semaglutide (Rybelsus) 14 mg Tab00169431430Listed by the FDA as Rybelsusoral semaglutide14 mgtabletNovo Nordisk Pharmaceutical Industries, LP | 31,521.91 (Schedule G, line 208, page 15 of the filing PDF) | 56 |
| 209 | Retacrit 40,000 units/mL SOLN00069130904Listed by the FDA as Retacritepoetin alfa-epbx40,000 IU/mLinjection, solutionPfizer Laboratories Div Pfizer Inc | 30,873.76 (Schedule G, line 209, page 15 of the filing PDF) | 160 |
| 210 | durvalumab (Imfinzi) 860 mg in sodium chloride 0.9% 250 mL IVPB0310450012 | 30,287.32 (Schedule G, line 210, page 16 of the filing PDF) | 20 |
| 211 | eltrombopag olamine (Promacta) 50 mg tablet00078068615Listed by the FDA as Promactaeltrombopag olamine50 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 30,287.32 (Schedule G, line 211, page 16 of the filing PDF) | 19 |
| 212 | HyperRAB 300 units/mL SOLN13533031801Listed by the FDA as HyperRABrabies immune globulin (human)300 IU/mLinjection, solutionGrifols USA, LLC | 29,908.80 (Schedule G, line 212, page 16 of the filing PDF) | 39 |
| 213 | MPB Kyprolis 30 mg inj pwd76075010201Listed by the FDA as Kyproliscarfilzomib30 mg/15 mLinjection, powder, lyophilized, for solutionOnyx Pharmaceuticals, Inc. | 29,558.77 (Schedule G, line 213, page 16 of the filing PDF) | 34 |
| 214 | Enbrel Mini PF cart 50 mg/mL 458406004404Listed by the FDA as Enbreletanercept50 mg/mLsolutionImmunex Corporation | 29,331.31 (Schedule G, line 214, page 16 of the filing PDF) | 301 |
| 215 | MPB Jakafi 25 mg tab 6050881002560Listed by the FDA as Jakafiruxolitinib25 mgtabletIncyte Corporation | 29,049.16 (Schedule G, line 215, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 216 | risankizumab-rzaa (Skyrizi) 150 mg/mL Syrg00074105001Listed by the FDA as Skyrizirisankizumab-rzaa150 mg/mLinjectionAbbVie Inc. | 28,799.24 (Schedule G, line 216, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 217 | semaglutide, weight loss, (Wegovy) 0.5 mg/0.5 mL pen-injector00169450514Listed by the FDA as Wegovysemaglutide0.5 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 28,727.42 (Schedule G, line 217, page 16 of the filing PDF) | 51 |
| 218 | MPB Bavencio 200 mg/10 mL SDV44087353501Listed by the FDA as Bavencioavelumab20 mg/mLinjection, solution, concentrateEMD Serono, Inc. | 27,909.00 (Schedule G, line 218, page 16 of the filing PDF) | 20 |
| 219 | MPB Xolair 300 mg/2 mL auto inj50242022755Listed by the FDA as Xolairomalizumab300 mg/2 mLinjection, solutionGenentech, Inc. | 27,716.39 (Schedule G, line 219, page 16 of the filing PDF) | 15 |
| 220 | octreotide LAR 30 mg PWDI00078082581Listed by the FDA as Sandostatin LAR Depotoctreotide acetatekitNovartis Pharmaceuticals Corporation | 27,694.33 (Schedule G, line 220, page 16 of the filing PDF) | 19 |
| 221 | inclisiran (Leqvio) 284 mg/1.5 mL Syrg00078100060Listed by the FDA as Leqvioinclisiran284 mg/1.5 mLinjection, solutionNovartis Pharmaceuticals Corporation | 27,611.19 (Schedule G, line 221, page 16 of the filing PDF) | 12 |
| 222 | Vumerity 231 mg cap64406002003Listed by the FDA as Vumeritydiroximel fumarate231 mgcapsuleBiogen Inc. | 27,114.78 (Schedule G, line 222, page 16 of the filing PDF) | 10 |
| 223 | MPB Apretude 600 mg/3 mL kit49702026423Listed by the FDA as ApretudecabotegravirkitViiV Healthcare Company | 27,025.74 (Schedule G, line 223, page 16 of the filing PDF) | 9 |
| 224 | Incruse Ellipta 62.5 mcg inh00173087310Listed by the FDA as Incruse Elliptaumeclidinium62.5 mcgaerosol, powderGlaxoSmithKline LLC | 27,020.82 (Schedule G, line 224, page 16 of the filing PDF) | 228 |
| 225 | Rybelsus 7 mg tablet00169430730Listed by the FDA as Rybelsusoral semaglutide7 mgtabletNovo Nordisk Pharmaceutical Industries, LP | 26,870.76 (Schedule G, line 225, page 16 of the filing PDF) | 46 |
| 226 | niraparib (Zejula) 200 mg Tab00173091213Listed by the FDA as Zejulaniraparib200 mgtablet, film coatedGlaxoSmithKline LLC | 26,837.74 (Schedule G, line 226, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 227 | Pomalyst 2 mg capsule59572050221Listed by the FDA as Pomalystpomalidomide2 mgcapsuleCelgene Corporation | 26,722.29 (Schedule G, line 227, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 228 | Revlimid 10 mg capsule59572041028Listed by the FDA as Revlimidlenalidomide10 mgcapsuleCelgene Corporation | 25,789.86 (Schedule G, line 228, page 16 of the filing PDF) | 21 |
| 229 | MPB Cyramza 500 mg/50 mL SDV00002767801Listed by the FDA as Cyramzaramucirumab10 mg/mLsolutionEli Lilly and Company | 25,640.12 (Schedule G, line 229, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 230 | Paxlovid new 300/100 mg T standard00069532130Listed by the FDA as Paxlovidnirmatrelvir and ritonavirkitPfizer Laboratories Div Pfizer Inc | 25,508.11 (Schedule G, line 230, page 16 of the filing PDF) | 24 |
| 231 | RabAvert SUSR50632001001Listed by the FDA as RabAvertrabies vaccinekitBavarian Nordic A/S | 25,457.77 (Schedule G, line 231, page 16 of the filing PDF) | 63 |
| 232 | Deferiprone TB 500Mgtaro100@=@51672419601Listed by the FDA as Deferiprone500 mgtabletSun Pharmaceutical Industries, Inc. | 25,114.83 (Schedule G, line 232, page 16 of the filing PDF) | 11 |
| 233 | MPB Nerlynx 40 mg tab 18070437024018Listed by the FDA as Nerlynxneratinib40 mgtabletPuma Biotechnology, Inc. | 24,551.76 (Schedule G, line 233, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 234 | MPB Darzalex 400 mg/20 mL SDV57894050520Listed by the FDA as Darzalex IVdaratumumab100 mg/5 mLinjection, solution, concentrateJanssen Biotech, Inc. | 24,527.81 (Schedule G, line 234, page 16 of the filing PDF) | 14 |
| 235 | Olumiant tab 2 mg 3000002418230Listed by the FDA as Olumiantbaricitinib2 mgtablet, film coatedEli Lilly and Company | 24,451.97 (Schedule G, line 235, page 16 of the filing PDF) | 14 |
| 236 | Santyl 250 units/g OINT50484001030Listed by the FDA as Collagenase Santyl250 units/gointmentSmith & Nephew, Inc | 24,266.10 (Schedule G, line 236, page 16 of the filing PDF) | 41 |
| 237 | Dasatinib TB 100 mg APX 30@60505363103Listed by the FDA as Dasatinib100 mgtablet, film coatedApotex Corp. | 24,255.35 (Schedule G, line 237, page 16 of the filing PDF) | 15 |
| 238 | MPB Nerlynx 40 mg TB 13370437024033Listed by the FDA as Nerlynxneratinib40 mgtabletPuma Biotechnology, Inc. | 24,044.36 (Schedule G, line 238, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 239 | Adbry Autoinj 300 mg/2 mL 2PK50222035002Listed by the FDA as Adbrytralokinumab-ldrm300 mg/2 mLinjection, solutionLEO Pharma Inc. | 23,841.51 (Schedule G, line 239, page 16 of the filing PDF) | 11 |
| 240 | Opzelura crm 1.5% 60 g50881000705Listed by the FDA as Opzeluraruxolitinib15 mg/gcreamIncyte Corporation | 23,568.01 (Schedule G, line 240, page 16 of the filing PDF) | 21 |
| 241 | ritlecitinib (Litfulo) 50 mg cap00069033428Listed by the FDA as Litfuloritlecitinib50 mgcapsulePfizer Laboratories Div Pfizer Inc | 23,548.58 (Schedule G, line 241, page 16 of the filing PDF) | 10 |
| 242 | MPB Cabometyx 40 mg tab 3042388002546Listed by the FDA as Cabometyxcabozantinib40 mgtabletExelixis, Inc. | 23,252.10 (Schedule G, line 242, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 243 | Gilenya 0.5 mg capsule00078060715Listed by the FDA as Gilenyafingolimod hcl0.5 mgcapsuleNovartis Pharmaceuticals Corporation | 22,988.96 (Schedule G, line 243, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 244 | Hizentra 10 gram/50 mL syringe44206045525Listed by the FDA as Hizentrahuman immunoglobulin G0.2 g/mLliquidCSL Behring AG | 22,684.98 (Schedule G, line 244, page 16 of the filing PDF) | 40 |
| 245 | MPB Nplate 250 mcg/0.5 mL SDV55513022101Listed by the FDA as Nplateromiplostim250 mcg/0.5 mLinjection, powder, lyophilized, for solutionAmgen, Inc | 22,406.76 (Schedule G, line 245, page 16 of the filing PDF) | 24 |
| 246 | Neulasta Onpro 6 mg/0.6 mL SOSY55513019201Listed by the FDA as NeulastapegfilgrastimkitAmgen, Inc | 22,181.58 (Schedule G, line 246, page 16 of the filing PDF) | 89 |
| 247 | Invega Sustenna 156 mg kit50458056301Listed by the FDA as Invega Sustennapaliperidone palmitate156 mg/mLinjectionJanssen Pharmaceuticals, Inc. | 22,010.18 (Schedule G, line 247, page 16 of the filing PDF) | 28 |
| 248 | Erbitux VL 2 mg/mL 50 mL66733094823Listed by the FDA as Erbituxcetuximab2 mg/mLsolutionImClone LLC | 21,918.33 (Schedule G, line 248, page 17 of the filing PDF) | 42 |
| 249 | Mvasi SDV 400 mg/16 mL 155513020701Listed by the FDA as Mvasibevacizumab-awwb400 mg/16 mLinjection, solutionAmgen, Inc | 21,811.09 (Schedule G, line 249, page 17 of the filing PDF) | 31 |
| 250 | Exparel 1.3% SUSP65250013309Listed by the FDA as Exparelbupivacaine13.3 mg/mLinjection, suspension, liposomalPacira Pharmaceuticals, Inc. | 21,434.43 (Schedule G, line 250, page 17 of the filing PDF) | 156 |
| 251 | Abilify Maintena PF syr 400 mg59148007280Listed by the FDA as Abilify MaintenaaripiprazolekitOtsuka America Pharmaceutical, Inc. | 21,403.39 (Schedule G, line 251, page 17 of the filing PDF) | 16 |
| 252 | MPB Adcetris 50 mg VL LY DS51144005001Listed by the FDA as Adcetrisbrentuximab vedotin50 mg/10.5 mLinjection, powder, lyophilized, for solutionSeagen Inc. | 21,236.90 (Schedule G, line 252, page 17 of the filing PDF) | 6 |
| 253 | MPB Nplate 125 mcg/0.25 mL SDV55513022301Listed by the FDA as Nplateromiplostim125 mcg/0.25 mLinjection, powder, lyophilized, for solutionAmgen, Inc | 21,157.01 (Schedule G, line 253, page 17 of the filing PDF) | 25 |
| 254 | momelotinib 150 mg Tab81864010230Listed by the FDA as Ojjaaramomelotinib150 mgtabletGlaxoSmithKline LLC | 20,974.86 (Schedule G, line 254, page 17 of the filing PDF) | fewer than 6 (the count is not shown) |
| 255 | MPB Gamunex-C 40 g/400 mL13533080040Listed by the FDA as Gamunex-Cimmune globulin (human)10 g/100 mLinjectionGrifols USA, LLC | 20,957.62 (Schedule G, line 255, page 17 of the filing PDF) | 8 |
| 256 | Qulipta tab 60 mg00074709430Listed by the FDA as Quliptaatogepant60 mgtabletAbbVie Inc. | 20,742.41 (Schedule G, line 256, page 17 of the filing PDF) | 62 |
| 257 | Combivent Respimat 20-100 mcg00597002402Listed by the FDA as Combivent Respimatipratropium bromide and albuterol20 mcg; 100 mcgspray, meteredBoehringer Ingelheim Pharmaceuticals, Inc. | 20,675.81 (Schedule G, line 257, page 17 of the filing PDF) | 32 |
| 258 | Tivicay 50 mg TABS49702022813Listed by the FDA as Tivicaydolutegravir sodium50 mgtablet, film coatedViiV Healthcare Company | 20,187.12 (Schedule G, line 258, page 17 of the filing PDF) | 44 |
| 259 | TNKase 50 mg KIT50242017601Listed by the FDA as TNKasetenecteplasekitGenentech, Inc. | 19,982.29 (Schedule G, line 259, page 17 of the filing PDF) | 17 |
| 260 | Symbicort 160-4.5 mcg/ACT AERO00186037028Listed by the FDA as Symbicortbudesonide and formoterol fumarate dihydrate160 mcg; 4.5 mcgaerosolAstraZeneca Pharmaceuticals LP | 19,783.47 (Schedule G, line 260, page 17 of the filing PDF) | 623 |
| 261 | Stiolto Respimat inhaler (60)00597015561Listed by the FDA as Stiolto Respimattiotropium bromide and olodaterol3.124 mcg; 2.736 mcgspray, meteredBoehringer Ingelheim Pharmaceuticals, Inc. | 19,497.56 (Schedule G, line 261, page 17 of the filing PDF) | 134 |
| 262 | Breo Ellipta 100-25 mcg Inhalr00173085910Listed by the FDA as Breo Elliptafluticasone furoate and vilanterol trifenatate100 mcg; 25 mcgpowderGlaxoSmithKline LLC | 19,314.22 (Schedule G, line 262, page 17 of the filing PDF) | 214 |
| 263 | Veklury 100 mg SOLR61958290102Listed by the FDA as Vekluryremdesivir100 mginjection, powder, lyophilized, for solutionGilead Sciences, Inc. | 19,308.00 (Schedule G, line 263, page 17 of the filing PDF) | fewer than 6 (the count is not shown) |
| 264 | MPB Ibrance 100 mg cap 2100069018821Listed by the FDA as Ibrancepalbociclib100 mgcapsulePfizer Laboratories Div Pfizer Inc | 18,837.72 (Schedule G, line 264, page 17 of the filing PDF) | fewer than 6 (the count is not shown) |
| 265 | Entresto 49 mg-51 mg tablet00078077720Listed by the FDA as Entrestosacubitril and valsartan49 mg; 51 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 18,827.95 (Schedule G, line 265, page 17 of the filing PDF) | 141 |
| 266 | MPB Kyprolis 10 mg inj pwd76075010301Listed by the FDA as Kyproliscarfilzomib10 mg/5 mLinjection, powder, lyophilized, for solutionOnyx Pharmaceuticals, Inc. | 18,102.34 (Schedule G, line 266, page 17 of the filing PDF) | 55 |
| 267 | Steqeyma PFS 90 mg/mL 172606002801Listed by the FDA as Steqeymaustekinumab-stba90 mg/mLinjection, solutionCELLTRION USA, Inc. | 18,066.24 (Schedule G, line 267, page 17 of the filing PDF) | 16 |
| 268 | Epinephrine 0.3 mg auto-Inject00093598627Listed by the FDA as Epinephrine0.3 mg/0.3 mLinjectionTeva Pharmaceuticals USA, Inc. | 17,995.59 (Schedule G, line 268, page 17 of the filing PDF) | 193 |
| 269 | capivasertib (Truqap) 160 mg Tab00310950002Listed by the FDA as Truqapcapivasertib160 mgtablet, film coatedAstraZeneca Pharmaceuticals LP | 17,903.54 (Schedule G, line 269, page 17 of the filing PDF) | fewer than 6 (the count is not shown) |
| 270 | MPB Jakafi 5 mg tab 6050881000560Listed by the FDA as Jakafiruxolitinib5 mgtabletIncyte Corporation | 17,583.60 (Schedule G, line 270, page 17 of the filing PDF) | fewer than 6 (the count is not shown) |
| 271 | Ubrelvy 100 mg tablets00023650110Listed by the FDA as Ubrelvyubrogepant100 mgtabletAllergan, Inc. | 17,383.27 (Schedule G, line 271, page 17 of the filing PDF) | fewer than 6 (the count is not shown) |
| 272 | Entresto 97-103 mg TABS00078069620Listed by the FDA as Entrestosacubitril and valsartan97 mg; 103 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 17,208.00 (Schedule G, line 272, page 17 of the filing PDF) | 73 |
| 273 | Emgality inj pen 120 mg/mL 100002143611Listed by the FDA as Emgalitygalcanezumab-gnlm120 mg/mLinjection, solutionEli Lilly and Company | 16,740.44 (Schedule G, line 273, page 17 of the filing PDF) | 34 |
| 274 | Abraxane SDV 100 mg68817013450Listed by the FDA as Abraxanepaclitaxel100 mg/20 mLinjection, powder, lyophilized, for suspensionAbraxis BioScience, LLC | 16,692.96 (Schedule G, line 274, page 17 of the filing PDF) | 20 |
| 275 | Vraylar cap 1.5 mg 3061874011530Listed by the FDA as Vraylarcariprazine1.5 mgcapsule, gelatin coatedAllergan, Inc. | 16,176.21 (Schedule G, line 275, page 17 of the filing PDF) | 21 |
| 276 | Breo Ellipta 200-25 mcg Inhalr00173088210Listed by the FDA as Breo Elliptafluticasone furoate and vilanterol trifenatate200 mcg; 25 mcgpowderGlaxoSmithKline LLC | 16,169.19 (Schedule G, line 276, page 17 of the filing PDF) | 180 |
| 277 | Abilify Maintena 400 mg kit59148001971 | 15,548.74 (Schedule G, line 277, page 17 of the filing PDF) | 13 |
| 278 | Zerbaxa 1.5 (1-0.5) GM SOLR67919003001Listed by the FDA as Zerbaxaceftolozane and tazobactam1 g/10 mL; 0.5 g/10 mLinjection, powder, lyophilized, for solutionMerck Sharp & Dohme LLC | 15,272.11 (Schedule G, line 278, page 17 of the filing PDF) | 12 |
| 279 | Rexulti 1 mg TABS59148003713Listed by the FDA as Rexultibrexpiprazole1 mgtabletOtsuka America Pharmaceutical, Inc. | 15,260.53 (Schedule G, line 279, page 17 of the filing PDF) | 26 |
| 280 | Budesonide/FORM 160/4.5 mcg(120 inh)00310737020Listed by the FDA as Budesonide and Formoterol Fumarate Dihydrate160 mcg; 4.5 mcgaerosolAstraZeneca Pharmaceuticals LP | 15,060.51 (Schedule G, line 280, page 17 of the filing PDF) | 163 |
| 281 | Toujeo Max Solostr 300 units/mL00024587102Listed by the FDA as Toujeo Maxinsulin glargine300 units/mLinjection, solutionSanofi-Aventis U.S. LLC | 14,986.82 (Schedule G, line 281, page 17 of the filing PDF) | 14 |
| 282 | Gamunex-C 20 gram/200 mL vial13533080024Listed by the FDA as Gamunex-Cimmune globulin (human)10 g/100 mLinjectionGrifols USA, LLC | 14,740.04 (Schedule G, line 282, page 17 of the filing PDF) | 27 |
| 283 | Diprivan 200 mg/20 mL EMUL63323026929Listed by the FDA as Diprivanpropofol10 mg/mLinjection, emulsionFresenius Kabi USA, LLC | 14,634.45 (Schedule G, line 283, page 17 of the filing PDF) | 13,759 |
| 284 | MPB PHS Neulasta 6 mg/0.6 mL PFS55513019001Listed by the FDA as Neulastapegfilgrastim6 mg/0.6 mLinjectionAmgen, Inc | 14,595.41 (Schedule G, line 284, page 17 of the filing PDF) | 34 |
| 285 | Sivextro tab 200 mg 3067919004104Listed by the FDA as Sivextrotedizolid phosphate200 mgtablet, film coatedMerck Sharp & Dohme LLC | 14,261.32 (Schedule G, line 285, page 17 of the filing PDF) | fewer than 6 (the count is not shown) |
| 286 | Belrapzo inj 100 mg/4 mL42367052125Listed by the FDA as Belrapzobendamustine hydrochloride100 mg/4 mLinjectionEagle Pharmaceuticals, Inc | 14,216.67 (Schedule G, line 286, page 18 of the filing PDF) | 31 |
| 287 | Rexulti 0.5 mg TABS59148003613Listed by the FDA as Rexultibrexpiprazole0.5 mgtabletOtsuka America Pharmaceutical, Inc. | 14,104.88 (Schedule G, line 287, page 18 of the filing PDF) | 18 |
| 288 | Tymlos 80 mcg dose pen Injectr70539000102Listed by the FDA as Tymlosabaloparatide3.12 mg/1.56 mLinjection, solutionRadius Health, Inc. | 14,064.42 (Schedule G, line 288, page 18 of the filing PDF) | 75 |
| 289 | Dapagliflozin Propanediol 5 mg TABS66993045630Listed by the FDA as Dapagliflozin5 mgtablet, film coatedPrasco Laboratories | 14,044.19 (Schedule G, line 289, page 18 of the filing PDF) | 82 |
| 290 | Emgality inj PFS 120 mg 100002237711Listed by the FDA as Emgalitygalcanezumab-gnlm120 mg/mLinjection, solutionEli Lilly and Company | 13,758.92 (Schedule G, line 290, page 18 of the filing PDF) | 28 |
| 291 | MPB Leukine 250 mcg pwd SDV 571837584305Listed by the FDA as Leukinesargramostim250 mcg/mLinjection, powder, lyophilized, for solutionPartner Therapeutics, Inc. | 13,434.60 (Schedule G, line 291, page 18 of the filing PDF) | 24 |
| 292 | Invega Trinza PFS 546 mg 150458060801Listed by the FDA as Invega Trinzapaliperidone palmitate546 mg/1.75 mLinjection, suspension, extended releaseJanssen Pharmaceuticals, Inc | 13,414.18 (Schedule G, line 292, page 18 of the filing PDF) | fewer than 6 (the count is not shown) |
| 293 | Descovy 200 mg/25 mg tablets61958200201Listed by the FDA as Descovyemtricitabine and tenofovir alafenamide200 mg; 25 mgtabletGilead Sciences, Inc. | 13,203.41 (Schedule G, line 293, page 18 of the filing PDF) | 31 |
| 294 | Biktarvy 30-120-15 mg tablet61958250501Listed by the FDA as Biktarvybictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate30 mg; 120 mg; 15 mgtabletGilead Sciences, Inc. | 13,203.41 (Schedule G, line 294, page 18 of the filing PDF) | fewer than 6 (the count is not shown) |
| 295 | Vraylar cap 3 mg 3061874013030Listed by the FDA as Vraylarcariprazine3 mgcapsule, gelatin coatedAllergan, Inc. | 13,003.26 (Schedule G, line 295, page 18 of the filing PDF) | 17 |
| 296 | Venofer 20 mg/mL SOLN00517234010Listed by the FDA as Venoferiron sucrose20 mg/mLinjection, solutionAmerican Regent, Inc. | 12,929.08 (Schedule G, line 296, page 18 of the filing PDF) | 247 |
| 297 | Glatopa 40 mg/mL syringe00781325089Listed by the FDA as Glatopaglatiramer acetate40 mg/mLinjection, solutionSandoz Inc | 12,904.71 (Schedule G, line 297, page 18 of the filing PDF) | 27 |
| 298 | Tresiba Flextouch 100 units/mL00169266015Listed by the FDA as Tresibainsulin degludec100 units/mLinjection, solutionNovo Nordisk | 12,777.63 (Schedule G, line 298, page 18 of the filing PDF) | 99 |
| 299 | Privigen 5 g/50 mL SOLN44206043605Listed by the FDA as Privigenhuman immunoglobulin G5 g/50 mLliquidCSL Behring AG | 12,458.15 (Schedule G, line 299, page 18 of the filing PDF) | 43 |
| 300 | Tyenne auto inj 162 mg/0.9 mL 165219059601Listed by the FDA as Tyennetocilizumab-aazg162 mg/0.9 mLinjection, solutionFresenius Kabi USA, LLC | 12,390.60 (Schedule G, line 300, page 18 of the filing PDF) | 30 |
| 301 | Austedo XR 30 mg tablet68546047356Listed by the FDA as Austedo XRdeutetrabenazine30 mgtablet, film coated, extended releaseTeva Neuroscience, Inc. | 12,353.86 (Schedule G, line 301, page 18 of the filing PDF) | fewer than 6 (the count is not shown) |
| 302 | eltrombopag olamine (Promacta) 75 mg Tab00078068715Listed by the FDA as Promactaeltrombopag olamine75 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 12,225.88 (Schedule G, line 302, page 18 of the filing PDF) | fewer than 6 (the count is not shown) |
| 303 | Prezcobix tab 800 mg 3059676057530Listed by the FDA as Prezcobixdarunavir ethanolate and cobicistat800 mg; 150 mgtablet, film coatedJanssen Products, LP | 12,177.30 (Schedule G, line 303, page 18 of the filing PDF) | 10 |
| 304 | Mvasi SDV 100 mg/4 mL 155513020601Listed by the FDA as Mvasibevacizumab-awwb100 mg/4 mLinjection, solutionAmgen, Inc | 11,639.85 (Schedule G, line 304, page 18 of the filing PDF) | 92 |
| 305 | Rexulti 2 mg TABS59148003813Listed by the FDA as Rexultibrexpiprazole2 mgtabletOtsuka America Pharmaceutical, Inc. | 11,582.13 (Schedule G, line 305, page 18 of the filing PDF) | 17 |
| 306 | NovoLOG 100 units/mL SOLN00169750111Listed by the FDA as Novologinsulin aspart100 IU/mLinjection, solutionNovo Nordisk | 11,479.76 (Schedule G, line 306, page 18 of the filing PDF) | 75 |
| 307 | (no name printed)adalimumab-adbm (Cyltezo,CF, Pen) 40 mg/0.8 mL PnKt 00597037597 | 11,159.72 (Schedule G, line 307, page 18 of the filing PDF) | 13 |
| 308 | Genvoya tab 3061958190101Listed by the FDA as Genvoyaelvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide150 mg; 150 mg; 200 mg; 10 mgtabletGilead Sciences, Inc. | 11,145.92 (Schedule G, line 308, page 18 of the filing PDF) | fewer than 6 (the count is not shown) |
| 309 | Exparel 1.3% SUSP65250026609Listed by the FDA as Exparelbupivacaine13.3 mg/mLinjection, suspension, liposomalPacira Pharmaceuticals, Inc. | 10,998.39 (Schedule G, line 309, page 18 of the filing PDF) | 48 |
| 310 | Kerendia TB 10 mg 3050419054001Listed by the FDA as Kerendiafinerenone10 mgtablet, film coatedBayer HealthCare Pharmaceuticals Inc. | 10,930.24 (Schedule G, line 310, page 18 of the filing PDF) | 29 |
| 311 | Revlimid 5 mg capsule59572040528Listed by the FDA as Revlimidlenalidomide5 mgcapsuleCelgene Corporation | 10,588.67 (Schedule G, line 311, page 18 of the filing PDF) | 13 |
| 312 | Gemtesa TB 75 mg 3073336007530Listed by the FDA as Gemtesavibegron75 mgtablet, film coatedSumitomo Pharma America, Inc. | 10,501.54 (Schedule G, line 312, page 18 of the filing PDF) | 56 |
| 313 | Zoladex PF syr 3.6 mg SNGL DS70720095036Listed by the FDA as Zoladexgoserelin3.6 mgimplantTerSera Therapeutics LLC | 10,415.29 (Schedule G, line 313, page 18 of the filing PDF) | 13 |
| 314 | MPB Xolair 150 mg/mL auto inj50242021555Listed by the FDA as Xolair PFSomalizumab150 mg/mLinjection, solutionGenentech, Inc. | 10,356.21 (Schedule G, line 314, page 18 of the filing PDF) | 12 |
| 315 | Lantus Solostar 100 units/mL00088221905Listed by the FDA as Lantus Solostarinsulin glargine100 IU/mLinjection, solutionsanofi-aventis U.S. LLC | 10,335.03 (Schedule G, line 315, page 18 of the filing PDF) | 586 |
| 316 | glatiramer 40 mg/mL Syrg00378696112Listed by the FDA as Glatiramer Acetateglatiramer40 mg/mLinjection, solutionMylan Pharmaceuticals Inc. | 10,302.25 (Schedule G, line 316, page 18 of the filing PDF) | 14 |
| 317 | Abilify Maintena ER 300 mg kit59148023212Listed by the FDA as Abilify MaintenaaripiprazolekitOtsuka America Pharmaceutical, Inc. | 10,111.68 (Schedule G, line 317, page 18 of the filing PDF) | 7 |
| 318 | MPB Austedo 9 mg tab 6068546017160Listed by the FDA as Austedodeutetrabenazine9 mgtablet, coatedTeva Neuroscience, Inc. | 10,040.76 (Schedule G, line 318, page 18 of the filing PDF) | fewer than 6 (the count is not shown) |
| 319 | Caplyta 42 mg CAPS72060014240Listed by the FDA as Caplytalumateperone42 mgcapsuleIntra-Cellular Therapies, Inc | 9,948.89 (Schedule G, line 319, page 18 of the filing PDF) | 12 |
| 320 | Paxlovid standard dose 300/100 mg T00069504530Listed by the FDA as Paxlovidnirmatrelvir and ritonavirkitPfizer Laboratories Div Pfizer Inc | 9,608.60 (Schedule G, line 320, page 18 of the filing PDF) | 11 |
| 321 | Provocholine KIT64281011006Listed by the FDA as Provocholine Inhalation Solutionmethacholine chloride inhalation solutionkitMethapharm Inc. | 9,490.61 (Schedule G, line 321, page 18 of the filing PDF) | 75 |
| 322 | Dificid 200 mg TABS52015008001Listed by the FDA as Dificidfidaxomicin200 mgtablet, film coatedMerck Sharp & Dohme LLC | 9,483.82 (Schedule G, line 322, page 18 of the filing PDF) | 13 |
| 323 | AlbuRx 25% SOLN44206025110Listed by the FDA as AlbuRxalbumin (human)12.5 g/50 mLsolutionCSL Behring AG | 9,345.45 (Schedule G, line 323, page 18 of the filing PDF) | 157 |
| 324 | ferric carboxymaltose 750 mg/15 mL INJ00517065001Listed by the FDA as Injectaferferric carboxymaltose injection50 mg/mLinjection, solutionAmerican Regent, Inc. | 9,193.32 (Schedule G, line 324, page 19 of the filing PDF) | 25 |
| 325 | insulin aspart (NovoLOG Flexpen U-100 Insulin) 100 units/mL (3 mL) InPn00169633910Listed by the FDA as Novologinsulin aspart100 IU/mLinjection, solutionNovo Nordisk | 9,136.01 (Schedule G, line 325, page 19 of the filing PDF) | 134 |
| 326 | Yupelri Inhal sol175 mcg/3 mL 3049502080693Listed by the FDA as Yupelrirevefenacin175 mcg/3 mLsolutionViatris Specialty LLC | 9,110.93 (Schedule G, line 326, page 19 of the filing PDF) | 32 |
| 327 | Sofos/Velpa TB 400 mg/100 mg 2872626270101Listed by the FDA as Sofosbuvir and Velpatasvirvelpatasvir and sofosbuvir100 mg; 400 mgtablet, film coatedAsegua Therapeutics LLC | 9,033.63 (Schedule G, line 327, page 19 of the filing PDF) | fewer than 6 (the count is not shown) |
| 328 | Glucagon HCl (Diagnostic) 1 mg SOLR63323059303Listed by the FDA as GlucagonkitFresenius Kabi USA, LLC | 8,840.87 (Schedule G, line 328, page 19 of the filing PDF) | 81 |
| 329 | MPB Rituxan 500 mg/50 mL SDV50242005306Listed by the FDA as Rituxanrituximab10 mg/mLinjection, solutionGenentech, Inc. | 8,833.99 (Schedule G, line 329, page 19 of the filing PDF) | fewer than 6 (the count is not shown) |
| 330 | Acetaminophen 10 mg/mL SOLN24201010024Listed by the FDA as Acetaminophen10 mg/mLinjection, solutionHikma Pharmaceuticals USA Inc. | 8,507.32 (Schedule G, line 330, page 19 of the filing PDF) | 2,544 |
| 331 | Aimovig inj 140 mg/mL55513084301Listed by the FDA as Aimovigerenumab-aooe140 mg/mLinjection, solutionAmgen, Inc | 8,428.38 (Schedule G, line 331, page 19 of the filing PDF) | 68 |
| 332 | MPB Evenity 105 mg/1.17 mL PFS 255513099802Listed by the FDA as Evenityromosozumab-aqqg105 mg/1.17 mLinjection, solutionAmgen, Inc | 8,334.87 (Schedule G, line 332, page 19 of the filing PDF) | fewer than 6 (the count is not shown) |
| 333 | diazePAM 5 mg/mL SOLN00409127332Listed by the FDA as Diazepam5 mg/mLinjection, solutionHospira, Inc. | 8,131.07 (Schedule G, line 333, page 19 of the filing PDF) | 1,315 |
| 334 | Veozah tab 45 mg00469266030Listed by the FDA as Veozahfezolinetant45 mgtablet, film coatedAstellas Pharma US, Inc. | 7,925.27 (Schedule G, line 334, page 19 of the filing PDF) | 28 |
| 335 | EPINEPHrine 1 mg/10 mL SOSY76329331801Listed by the FDA as Epinephrine0.1 mg/mLinjectionInternational Medication Systems, Limited | 7,887.32 (Schedule G, line 335, page 19 of the filing PDF) | 324 |
| 336 | Budesonide/FORM 80/4.5 mcg (120 inh)00310737220Listed by the FDA as Budesonide and Formoterol Fumarate Dihydrate80 mcg; 4.5 mcgaerosolAstraZeneca Pharmaceuticals LP | 7,825.80 (Schedule G, line 336, page 19 of the filing PDF) | 93 |
| 337 | Symbicort 160-4.5 mcg inhaler00186037020Listed by the FDA as Symbicortbudesonide and formoterol fumarate dihydrate160 mcg; 4.5 mcgaerosolAstraZeneca Pharmaceuticals LP | 7,722.72 (Schedule G, line 337, page 19 of the filing PDF) | 130 |
| 338 | solriamfetoL (Sunosi) 150 mg Tab81968035101Listed by the FDA as Sunosisolriamfetol150 mgtablet, film coatedAxsome Therapeutics, Inc. | 7,521.47 (Schedule G, line 338, page 19 of the filing PDF) | 40 |
| 339 | Tremfya pen 200 mg/2 mL 257894065104Listed by the FDA as Tremfyaguselkumab200 mg/2 mLinjectionJanssen Biotech, Inc. | 7,507.70 (Schedule G, line 339, page 19 of the filing PDF) | fewer than 6 (the count is not shown) |
| 340 | Truxima SDV 500 mg/50 mL 163459010450Listed by the FDA as Truximarituximab-abbs10 mg/mLinjection, solutionCephalon, Inc. | 7,476.63 (Schedule G, line 340, page 19 of the filing PDF) | 7 |
| 341 | Tyenne PFS 162 mg/0.9 mL 165219058604Listed by the FDA as Tyennetocilizumab-aazg162 mg/0.9 mLinjection, solutionFresenius Kabi USA, LLC | 7,355.54 (Schedule G, line 341, page 19 of the filing PDF) | 18 |
| 342 | Zoryve crm 0.3% 60 g80610013060Listed by the FDA as Zoryveroflumilast3 mg/gcreamArcutis Biotherapeutics, Inc. | 7,330.84 (Schedule G, line 342, page 19 of the filing PDF) | 13 |
| 343 | Ajovy Autoinject 225 mg/1.5 mL 151759020210Listed by the FDA as Ajovyfremanezumab-vfrm225 mg/1.5 mLinjectionTeva Pharmaceuticals USA, Inc. | 7,191.78 (Schedule G, line 343, page 19 of the filing PDF) | 42 |
| 344 | Qulipta 30 mg tablets00074709630Listed by the FDA as Quliptaatogepant30 mgtabletAbbVie Inc. | 7,185.34 (Schedule G, line 344, page 19 of the filing PDF) | 20 |
| 345 | Retacrit 10,000 units/mL SOLN00069130810Listed by the FDA as Retacritepoetin alfa-epbx10,000 IU/mLinjection, solutionPfizer Laboratories Div Pfizer Inc | 7,101.84 (Schedule G, line 345, page 19 of the filing PDF) | 87 |
| 346 | Vascepa cap 1 g52937000120Listed by the FDA as Vascepaicosapent ethyl1,000 mgcapsuleAmarin Pharma Inc. | 7,076.80 (Schedule G, line 346, page 19 of the filing PDF) | 16 |
| 347 | Sublocade 100 mg/0.5 mL Syring12496010001Listed by the FDA as Sublocadebuprenorphine100 mgsolutionIndivior Inc. | 7,006.67 (Schedule G, line 347, page 19 of the filing PDF) | fewer than 6 (the count is not shown) |
| 348 | Cinvanti inj SDV 130 mg/18 mL 147426020101Listed by the FDA as Cinvantiaprepitant130 mg/18 mLinjection, emulsionHeron Therapeutics, Inc. | 6,980.75 (Schedule G, line 348, page 19 of the filing PDF) | 53 |
| 349 | ceFAZolin Sodium 1 g SOLR00143992490Listed by the FDA as Cefazolin330 mg/mLinjection, powder, for solutionHikma Pharmaceuticals USA Inc. | 6,973.80 (Schedule G, line 349, page 19 of the filing PDF) | 6,748 |
| 350 | Vraylar cap 4.5 mg 3061874014530Listed by the FDA as Vraylarcariprazine4.5 mgcapsule, gelatin coatedAllergan, Inc. | 6,894.24 (Schedule G, line 350, page 19 of the filing PDF) | 9 |
| 351 | Admelog SoloStar 100 units/mL SOPN00024592505Listed by the FDA as Admeloginsulin lispro100 units/mLinjection, solutionSanofi-Aventis U.S. LLC | 6,864.21 (Schedule G, line 351, page 19 of the filing PDF) | fewer than 6 (the count is not shown) |
| 352 | Plaquenil tab 200 mg59212056210Listed by the FDA as Plaquenilhydroxychloroquine sulfate200 mgtabletAdvanz Pharma (US) Corp. | 6,766.56 (Schedule G, line 352, page 19 of the filing PDF) | fewer than 6 (the count is not shown) |
| 353 | Vancomycin HCl 2,000 mg/400 mL SOLN70594004402Listed by the FDA as Vancomycin2 g/400 mLinjection, solutionXellia Pharmaceuticals USA LLC | 6,662.42 (Schedule G, line 353, page 19 of the filing PDF) | 419 |
| 354 | Ventolin HFA 108 (90 Base) mcg/ACT AERS00173068224Listed by the FDA as Ventolin HFAalbuterol sulfate90 mcgaerosol, meteredGlaxoSmithKline LLC | 6,423.57 (Schedule G, line 354, page 19 of the filing PDF) | 1,024 |
| 355 | MPB Pemgarda 500 mg/4 mL 9 DS81960003103Listed by the FDA as Pemgardapemivibart125 mg/mLinjectionInvivyd, Inc | 6,350.00 (Schedule G, line 355, page 19 of the filing PDF) | fewer than 6 (the count is not shown) |
| 356 | Sincalide 5 mcg SOLR72266024805Listed by the FDA as Sincalide5 mcg/5 mLinjection, powder, lyophilized, for solutionFosun Pharma USA Inc | 6,336.67 (Schedule G, line 356, page 19 of the filing PDF) | 98 |
| 357 | PHENobarbital Sodium 130 mg/mL SOLN00641047725Listed by the FDA as Phenobarbital Sodium130 mg/mLinjectionHikma Pharmaceuticals USA Inc. | 6,281.50 (Schedule G, line 357, page 19 of the filing PDF) | 96 |
| 358 | Myfembree TB 40/1/0.5 mg 2872974041501Listed by the FDA as Myfembreerelugolix, estradiol hemihydrate, and norethindrone acetate40 mg; 1 mg; 0.5 mgtablet, film coatedSumitomo Pharma America, Inc | 6,210.60 (Schedule G, line 358, page 19 of the filing PDF) | 11 |
| 359 | Elitek 1.5 mg SOLR00024515010Listed by the FDA as ElitekrasburicasekitSanofi-Aventis U.S. LLC | 6,203.74 (Schedule G, line 359, page 19 of the filing PDF) | fewer than 6 (the count is not shown) |
| 360 | Admelog 100 units/mL SOLN00024592605Listed by the FDA as Admeloginsulin lispro100 units/mLinjection, solutionSanofi-Aventis U.S. LLC | 6,142.50 (Schedule G, line 360, page 19 of the filing PDF) | 1,510 |
| 361 | MPB Darzalex 100 mg/5 mL SDV57894050505Listed by the FDA as Darzalex IVdaratumumab100 mg/5 mLinjection, solution, concentrateJanssen Biotech, Inc. | 6,127.96 (Schedule G, line 361, page 19 of the filing PDF) | 14 |
| 362 | MPB Onivyde 43 mg/10 mL SDV15054004301Listed by the FDA as Onivydeirinotecan hydrochloride4.3 mg/mLinjection, powder, for solutionIpsen Biopharmaceuticals, Inc. | 6,047.44 (Schedule G, line 362, page 20 of the filing PDF) | fewer than 6 (the count is not shown) |
| 363 | Lisdexamf DIM CP 70 mg ALV 100@47781056801Listed by the FDA as Lisdexamfetamine Dimesylate70 mgcapsuleAlvogen Inc. | 6,029.76 (Schedule G, line 363, page 20 of the filing PDF) | 16 |
| 364 | Feraheme vial 510 mg 17 mL 159338077501Listed by the FDA as Ferahemeferumoxytol510 mg/17 mLinjectionAMAG Pharmaceuticals, Inc | 6,019.56 (Schedule G, line 364, page 20 of the filing PDF) | 53 |
| 365 | Kinevac vial 5 mcg 1000270055615Listed by the FDA as Kinevacsincalide5 mcg/5 mLinjection, powder, lyophilized, for solutionBracco Diagnostics Inc. | 5,996.20 (Schedule G, line 365, page 20 of the filing PDF) | fewer than 6 (the count is not shown) |
| 366 | Furosemide 10 mg/mL SOLN00409610210Listed by the FDA as Furosemide10 mg/mLinjection, solutionHospira, Inc. | 5,931.54 (Schedule G, line 366, page 20 of the filing PDF) | 1,281 |
| 367 | Cimzia pre filled syr 2x200 mg50474071079Listed by the FDA as Cimziacertolizumab pegol200 mg/mLinjection, solutionUCB, Inc. | 5,890.27 (Schedule G, line 367, page 20 of the filing PDF) | 93 |
| 368 | ProvayBlue 50 mg/10 mL SOLN00517037405Listed by the FDA as Provaybluemethylene blue5 mg/mLinjectionAmerican Regent, Inc. | 5,827.09 (Schedule G, line 368, page 20 of the filing PDF) | 81 |
| 369 | Liletta (52 mg) 20.1 mcg/DAY IUD00023585801Listed by the FDA as Lilettalevonorgestrel52 mgintrauterine deviceAllergan, Inc. | 5,717.59 (Schedule G, line 369, page 20 of the filing PDF) | 18 |
| 370 | MPB Xolair 75 mg/0.5 mL auto inj50242021455Listed by the FDA as Xolair PFSomalizumab75 mg/0.5 mLinjection, solutionGenentech, Inc. | 5,681.46 (Schedule G, line 370, page 20 of the filing PDF) | 13 |
| 371 | PHENobarbital Sodium 130 mg/mL SOLN54288013710Listed by the FDA as Phenobarbital Sodium130 mg/mLinjectionBPI Labs LLC | 5,679.52 (Schedule G, line 371, page 20 of the filing PDF) | 42 |
| 372 | Copaxone 40 mg pref syr 1268546032512Listed by the FDA as Copaxoneglatiramer acetate40 mg/mLinjection, solutionTeva Neuroscience, Inc. | 5,630.09 (Schedule G, line 372, page 20 of the filing PDF) | fewer than 6 (the count is not shown) |
| 373 | MPB Tecentriq 840 mg/14 mL SDV50242091801Listed by the FDA as Tecentriqatezolizumab840 mg/14 mLinjection, solutionGenentech, Inc. | 5,556.49 (Schedule G, line 373, page 20 of the filing PDF) | fewer than 6 (the count is not shown) |
| 374 | Praluent 75 mg/mL pen61755002002Listed by the FDA as Praluentalirocumab75 mg/mLinjection, solutionRegeneron Pharmaceuticals, Inc. | 5,552.53 (Schedule G, line 374, page 20 of the filing PDF) | 161 |
| 375 | Invega Sustenna 117 mg kit50458056201Listed by the FDA as Invega Sustennapaliperidone palmitate117 mg/0.75 mLinjectionJanssen Pharmaceuticals, Inc. | 5,538.05 (Schedule G, line 375, page 20 of the filing PDF) | 9 |
| 376 | MPB Qutenza 8% 179 mg patch 472512093001Listed by the FDA as QutenzacapsaicinkitAveritas Pharma Inc | 5,457.25 (Schedule G, line 376, page 20 of the filing PDF) | fewer than 6 (the count is not shown) |
| 377 | Lupron Depot 22.5 mg KT 3346-0300074334603Listed by the FDA as Lupron Depotleuprolide acetatekitAbbVie Inc. | 5,353.70 (Schedule G, line 377, page 20 of the filing PDF) | 18 |
| 378 | Bimzelx 320 mg/2 mL PFS kit50474078378Listed by the FDA as Bimzelxbimekizumab320 mg/2 mLinjection, solutionUCB, Inc. | 5,327.36 (Schedule G, line 378, page 20 of the filing PDF) | fewer than 6 (the count is not shown) |
| 379 | upadacitinib (Rinvoq) 45 mg Tb2400074104328Listed by the FDA as Rinvoqupadacitinib45 mgtablet, extended releaseAbbVie Inc. | 5,276.29 (Schedule G, line 379, page 20 of the filing PDF) | fewer than 6 (the count is not shown) |
| 380 | Gvoke HypoPen 2-pack 1 mg/0.2 mL72065012112Listed by the FDA as Gvoke HypoPen 1 mg Auto-Injectorglucagon injection, solution1 mg/0.2 mLinjection, solutionXeris Pharmaceuticals, Inc. | 5,272.83 (Schedule G, line 380, page 20 of the filing PDF) | 15 |
| 381 | Emerphed 5 mg/mL SOLN14789025010Listed by the FDA as Emerphedephedrine sulfate5 mg/mLinjectionNexus Pharamaceuticals Inc. | 5,200.59 (Schedule G, line 381, page 20 of the filing PDF) | 743 |
| 382 | Ketorolac Tromethamine 30 mg/mL SOLN63323016201Listed by the FDA as Ketorolac Tromethamine30 mg/mLinjection, solutionFresenius Kabi USA, LLC | 5,196.11 (Schedule G, line 382, page 20 of the filing PDF) | 5,762 |
| 383 | Albutero Sul HFA90 mcg PRAS18 g@66993001968Listed by the FDA as Albuterol Sulfate HFA90 mcgaerosol, meteredPrasco Laboratories | 5,169.08 (Schedule G, line 383, page 20 of the filing PDF) | 261 |
| 384 | ramucirumab 100 mg/10 mL INJ00002766901Listed by the FDA as Cyramzaramucirumab10 mg/mLsolutionEli Lilly and Company | 5,082.86 (Schedule G, line 384, page 20 of the filing PDF) | fewer than 6 (the count is not shown) |
| 385 | Biktarvy tab 50/200/25 mg 3061958250101Listed by the FDA as Biktarvybictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate50 mg; 200 mg; 25 mgtabletGilead Sciences, Inc. | 5,024.30 (Schedule G, line 385, page 20 of the filing PDF) | fewer than 6 (the count is not shown) |
| 386 | Praluent2x150 mg Prefilled pens61755002102Listed by the FDA as Praluentalirocumab150 mg/mLinjection, solutionRegeneron Pharmaceuticals, Inc. | 5,020.76 (Schedule G, line 386, page 20 of the filing PDF) | 23 |
| 387 | Acetylcysteine 200 mg/mL SOLN55150025930Listed by the FDA as Acetylcysteine6 g/30 mLinjection, solutionEugia US LLC | 5,020.50 (Schedule G, line 387, page 20 of the filing PDF) | 117 |
No row matches. | |||
| Total Prescription Drugs individually under $5,000 | 2,341,457.11 (Schedule G, row for amounts under $5,000, page 20 of the filing PDF) | 257,621 (Schedule G, claims on the row for amounts under $5,000, page 20 of the filing PDF) | |
| Total Costs of Prescription Drugs Obtained Through 340B Program Claimed for Reimbursement | 44,095,350.32 (Schedule G, printed total, page 20 of the filing PDF) | 332,510 (Schedule G, printed claims total, page 20 of the filing PDF) | |
The rows at the foot of the table are always shown. The sum above does not include them.
What “fewer than 6” means. A count of 1 to 5 is not shown on this site or in its data files. Methods, section 9, says how.
Amounts and counts are the filer’s own, in US dollars. They are written here with commas between thousands, and an amount filed with one decimal place is written with two. No value is changed: the filing and the download keep each figure as typed.
Drug names are the filer’s own words. Filers type them in many ways, so this page writes them one way: capitals, spaces, unit names such as mg and mL, a zero before a decimal point, and commas in long numbers. No word is changed, spelled out or left out, and shorthand stays as the filer typed it. The filing and the download keep each name as typed, and a search here reads both.
“Listed by the FDA as” is not part of the filing. It is the name, ingredient, strength, form and labeler that the U.S. Food and Drug Administration’s National Drug Code Directory lists for the row’s code, as downloaded on 11 November 2026. 381 of the 387 rows have one. A row has none when its code is not filed as one 11-digit code or the directory has never listed it. Where the directory has since dropped a code, the name is kept as it was last listed, and the line says so. The directory’s capitals, strengths and unit names are written one way on this page. How a code is matched
Source
- Filing PDF
- Open Schedule G on the State of Rhode Island's website
- SHA-256
- 4c51e84a5a25f096f4e626d8e7c794404bee305d5f2be7d453642a696448d20e
- Retrieved
- 11 November 2026
- Pages used
- 10 to 20 of 22